Aerosolized compositions containing mitochondria and methods of use thereof
Aerosolized mitochondrial compositions delivered via the respiratory tract provide an effective alternative to invasive methods, improving lung function and treating pulmonary disorders by targeting mitochondria to lung tissues.
Patent Information
- Application Number
- JP2021560961
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-04-15
- Filing Date
- 2020-04-15
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2040-04-15
AI Technical Summary
Current treatments for mitochondrial-related disorders often require invasive administration methods, such as intramuscular and intraarterial injections, which limit the ability to target mitochondria to various sites effectively for therapeutic purposes.
Aerosolized compositions containing mitochondria are administered via the respiratory tract using devices like nebulizers, allowing for targeted delivery to lung tissues and other sites, enhancing therapeutic efficacy.
The aerosolized administration of mitochondria effectively targets lung tissues, improving respiratory function and reducing damage from conditions like acute lung injury and ischemia/reperfusion injury, with potential applications in treating various pulmonary disorders and enhancing organ function.
Smart Images

Figure 0007590341000001 
Figure 0007590341000002 
Figure 0007590341000003
Abstract
Description
[Technical field]
[0001] Claiming priority This application claims the benefit of U.S. Provisional Application No. 62 / 834,020, filed April 15, 2019, the entire contents of which are incorporated herein by reference.
[0002] The present disclosure relates to aerosolized compositions containing mitochondria, methods of preparing and using such compositions, and devices for administering such compositions. [Background technology]
[0003] Mitochondria are double membrane-bound organelles found in the cytoplasm of nucleated eukaryotic cells. Mitochondria are found in almost all cells of the human body except red blood cells. Mitochondria are the primary site of cellular energy metabolism, producing adenosine triphosphate (ATP) for different cellular functions. Typically, more than 90% of a cell's requirement for ATP is supplied by the cell's own mitochondria.
[0004] Mitochondria are composed of two concentric membranes with specialized functions: the inner mitochondrial membrane contains the proteins for ATP synthase, and the outer mitochondrial membrane, which contains many essential membrane proteins, surrounds the entire organelle.
[0005] The structure of mitochondria bears striking similarities to some modern prokaryotes. In fact, mitochondria are thought to have originated from an ancient symbiosis when an nucleated cell engulfed an aerobic prokaryote. In the symbiotic relationship, the host cell became dependent on the engulfed prokaryote for energy production, and the prokaryotic cell began to depend on the protective environment provided by the host cell.
[0006] Due to the key function of mitochondria in cellular metabolism, damage and dysfunction in mitochondria can cause various human diseases. Damage to mitochondria can be caused by injury, toxicity, chemotherapy, and age-related changes. In particular, ischemia / reperfusion injury can cause mitochondrial dysfunction, which will negatively affect oxygen consumption and energy synthesis. Treatment involving mitochondria may be particularly useful for mitochondria-related disorders. Some early treatments involve administering mitochondria by intramuscular and intraarterial injection. It is necessary to administer mitochondria to various target sites of subjects via different administration routes for different purposes. Summary of the Invention [Means for solving the problem]
[0007] The present disclosure provides compositions (e.g., aerosolized compositions) containing mitochondria, methods of preparing and using the compositions, and devices for administering the compositions. In one aspect, the present disclosure provides a method of administering a composition containing mitochondria or a complex mitochondrial drug via the airways. In some embodiments, the composition is an aerosolized composition. In some embodiments, the composition is a liquid solution.
[0008] In one aspect, the disclosure relates to a method of treating a subject suffering from a respiratory disorder, the method comprising administering to the subject via the respiratory tract a therapeutically effective amount of a composition comprising mitochondria.
[0009] In some embodiments, the composition is an aerosolized composition, hi some embodiments, the composition is converted to aerosol form prior to administration to a subject by using a nebulizer, a vaporizer, a nasal spray, a pressurized metered dose inhaler, or a breath-activated pressurized metered dose inhaler.
[0010] In some embodiments, the aerosol form of the composition comprises droplets having a median size of 0.01 to 1000 microliters (e.g., 0.1 to 1000 microliters, 1 to 1000 microliters, 0.1 to 100 microliters, 0.1 to 500 microliters, or 1 to 500 microliters). In some embodiments, the droplets have a size of at least 0.01, 0.1, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, or 1000 microliters. In some embodiments, the droplets have a size of less than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, or 1000 microliters.
[0011] In some embodiments, the composition comprises respiration-competent mitochondria.
[0012] In some embodiments, the subject is suffering from respiratory failure, respiratory depression, pneumonia, lung cancer, wrinkles, alopecia, and / or cancer, hi some embodiments, the subject is suffering from acute lung injury.
[0013] In some embodiments, the concentration of mitochondria in the composition is about 1×10 4 ~5×10 9 ml -1 (For example, about 1×10 5 ~5×10 8 ml -1 , 1×10 6 ~5×10 8 ml -1 , 1×10 7 ~5×10 8 ml -1 , 1×10 5 ~1×10 8 ml -1 , 1×10 6 ~1×10 8 ml -1, 1×10 7 ~1×10 8 ml -1 , 1×10 6 ~5×10 7 ml -1 , 1×10 6 ~1×10 7 ml -1 , 1×10 6 ~5×10 7 ml -1 , 5×10 6 ~1×10 8 ml -1 In some embodiments, the concentration is at least or about 1×10 4 ml -1 , 5×10 4 ml -1 , 1×10 5 ml -1 , 5×10 5 ml -1 , 1×10 6 ml -1 , 5×10 6 ml -1 , 1×10 7 ml -1 , 5×10 7 ml -1 , 1×10 8 ml -1 , 5×10 8 ml -1 , or 1 × 10 9 ml -1 , 5×10 9 ml -1 , or 1 × 10 10 ml -1 In some embodiments, the concentration is 1×10 4 ml -1 , 5×10 4 ml -1 , 1×10 5 ml -1 , 5×10 5 ml -1 , 1×10 6 ml -1 , 5×10 6 ml -1 , 1×10 7 ml -1 , 5×10 7 ml -1, 1×10 8 ml -1 , 5×10 8 ml -1 , or 1 × 10 9 ml -1 , 5×10 9 ml -1 , or 1 × 10 10 ml -1 is less than.
[0014] In some embodiments, the subject receives 1×10 5 ~1×10 9 mitochondria (e.g., 1 x 10 per dose) 5 ~5×10 8 pieces, 1×10 6 ~5×10 8 pieces, 1×10 7 ~5×10 8 pieces, 1×10 5 ~1×10 8 pieces, 1×10 6 ~1×10 8 pieces, 1×10 7 ~1×10 8 pieces, 1×10 6 ~5×10 7 pieces, 1×10 6 ~1×10 7 pieces, 1×10 6 ~5×10 7 pieces, 5×10 6 ~1×10 8 In some embodiments, the dose is at least 1 x 10 mitochondria per dose. 4 pieces, 5×10 4 pieces, 1×10 5 pieces, 5×10 5 pieces, 1×10 6 pieces, 5×10 6 pieces, 1×10 7 pieces, 5×10 7 pieces, 1×10 8 pieces, 5×10 8 pcs or 1×10 9 pieces, 5×10 9 Pieces or 1 x 10 10 In some embodiments, the dose is 1 x 10 mitochondria per dose.4 pieces, 5×10 4 pieces, 1×10 5 pieces, 5×10 5 pieces, 1×10 6 pieces, 5×10 6 pieces, 1×10 7 pieces, 5×10 7 pieces, 1×10 8 pieces, 5×10 8 Pieces or 1 x 10 9 pieces, 5×10 9 Pieces or 1 x 10 10 There are less than 10 mitochondria.
[0015] In some embodiments, the mitochondria are autologous, allogeneic, or xenogeneic.
[0016] In some embodiments, the composition has a pH of 7 to 8. + - Further comprising a solution selected from the group consisting of HEPES, saline, phosphate buffered saline (PBS), serum, and plasma.
[0017] In some embodiments, the composition further comprises one or more osmolytes selected from the group consisting of trehalose, sucrose, mannose, glycine, proline, glycerol, mannitol, sorbitol, betaine, and sarcosine.
[0018] In some embodiments, the composition further comprises a pharmaceutical agent. In some embodiments, the composition further comprises a pharma- ceutically acceptable diluent, excipient, or carrier.
[0019] In some embodiments, the composition further comprises a therapeutic agent or a diagnostic agent, wherein the therapeutic agent or the diagnostic agent is covalently linked to, embedded within, or internalized within the mitochondria. In some embodiments, the therapeutic agent or the diagnostic agent is a therapeutic diagnostic agent. In some embodiments, the therapeutic agent or the diagnostic agent comprises an antibody or an antigen-binding fragment thereof. In some embodiments, the therapeutic agent or the diagnostic agent is covalently linked to the mitochondria.
[0020] In some embodiments, the therapeutic agent or the diagnostic agent is embedded or internalized within the mitochondria.
[0021] In some embodiments, the mitochondria are genetically modified.
[0022] In some embodiments, the mitochondrion comprises an exogenous polypeptide.
[0023] In some embodiments, the mitochondrion comprises an exogenous polynucleotide, DNA, RNA, mRNA, microRNA, nuclear RNA, or siRNA.
[0024] In one aspect, the present disclosure relates to an aerosolized composition comprising a plurality of droplets comprising a buffer, at least one droplet in the plurality of droplets comprising at least one mitochondrion.
[0025] In some embodiments, the buffer is selected from the group consisting of K+-HEPES having a pH of 7-8, saline, phosphate buffered saline (PBS), serum, and plasma.
[0026] In some embodiments, the composition further comprises one or more osmolytes selected from the group consisting of trehalose, sucrose, mannose, glycine, proline, glycerol, mannitol, sorbitol, betaine, and sarcosine.
[0027] In some embodiments, the composition further comprises a pharmaceutical agent.
[0028] In some embodiments, the composition further comprises a pharma- ceutically acceptable diluent, excipient, or carrier.
[0029] In some embodiments, the composition further comprises a therapeutic agent or a diagnostic agent, which is covalently linked to, embedded within, or internalized within the mitochondria.
[0030] In some embodiments, the mitochondrial drug is selected from the group consisting of a therapeutic drug, a chemotherapeutic drug, or a diagnostic drug.
[0031] In some embodiments, the mitochondrial drug comprises an antibody or antigen-binding fragment.
[0032] In some embodiments, the mitochondrial drug is covalently linked to the mitochondria, hi some embodiments, the mitochondrial drug is embedded or internalized within the mitochondria.
[0033] In some embodiments, the plurality of droplets has a median size between 1 and 1000 microliters.
[0034] In some embodiments, the mitochondria are genetically modified.
[0035] In some embodiments, the mitochondrion comprises an exogenous polypeptide.
[0036] In some embodiments, the mitochondrion comprises an exogenous polynucleotide.
[0037] In some embodiments, the mitochondria are incubated with a composition comprising the enzyme prior to administration to the subject.
[0038] In some embodiments, the composition comprises autologous mitochondria, allogeneic mitochondria, heterologous mitochondria, or a mixture thereof.
[0039] In one aspect, the disclosure relates to a device for delivering mitochondria via the airways of a subject, the device comprising a housing, a reservoir disposed within the housing for a composition comprising mitochondria, an aerosol generator for generating the composition in aerosolized form, and an outlet through which the composition is delivered to the airways of the subject.
[0040] In some embodiments, the device is a nebulizer, a nose spray, or a sprayer. In some embodiments, the aerosol generator is an ultrasonic nebulizer.
[0041] In some embodiments, the aerosol generator is a vibrating mesh device. In some embodiments, the aerosol generator comprises an air compressor that passes compressed air through the composition, converting the composition into an aerosol form.
[0042] In one aspect, the disclosure provides a device for delivering mitochondria via the airways of a subject, the device comprising a housing, a composition comprising mitochondria disposed within the housing, and an outlet configured to deliver the composition from the housing to the airways of the subject and aerosolize the composition as it passes therethrough.
[0043] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which this invention belongs. Methods and materials for use in the present invention are described herein, and other suitable methods and materials known in the art can also be used. The materials, methods, and examples are illustrative only and are not intended to be limiting. All publications, patent applications, patents, sequences, database entries, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control.
[0044] Other features and advantages of the invention will be apparent from the following detailed description and drawings, and from the claims. [Brief description of the drawings]
[0045] [Figure 1] FIG. 1 is a schematic diagram showing a method for isolating mitochondria. [Figure 2A] Skeletal muscle tissue obtained using a biopsy punch. [Figure 2B] Microscopic images of isolated mitochondria under phase contrast illumination (bright field, BF) (left panel), under fluorescence labeled with MitoTracker Red CMXRos (middle panel), and merged images (right panel). [Figure 2C] 1 is a plot showing the results for mitochondrial yield per gram of tissue wet weight. [Figure 2D] 1 is a transmission electron microscope image of isolated mitochondria. [Figure 2E] 1 is a bar graph showing the results of an activity assay for mitochondrial complexes I-V. [Figure 2F] 1 is a bar graph showing results for state 3 (active) oxygen consumption (ADP stimulated respiration). [Figure 2G]FIG. 1 is a bar graph showing results for the respiratory control index (RCI, state 3 / state 4) for malate-induced (complex I) and succinate-induced (complex II) oxygen consumption in autologous mitochondria from pectoralis major muscle. [Figure 3A] 13 is a composite microscopy image showing transplanted mitochondria localized within cardiomyocytes. [Figure 3B] 13 is a composite microscopy image showing transplanted mitochondria localized within cardiomyocytes. [Figure 3C] 13 is a composite microscopy image showing transplanted mitochondria localized within cardiomyocytes. [Figure 3D] 13 is a composite microscopy image showing transplanted mitochondria localized within cardiomyocytes. [Figure 4A] Representative transverse images acquired by positron emission tomography (PET) of rats administered 18F-rhodamine 6-G mitochondria (6 x 107) delivered to the lung by intravascular infusion via the pulmonary artery. [Figure 4B] 1 shows representative coronal images acquired by PET in a rat treated with 18F-rhodamine 6-G mitochondria (6×10 7 ) delivered to the lung by vascular infusion via the pulmonary artery. [Figure 4C] Representative images of the lungs acquired by PET from a rat administered 18F-rhodamine 6-G mitochondria (6×10 7 ) delivered to the lungs by vascular infusion via the pulmonary artery. [Figure 5A] 13 shows images of immunohistochemical staining of mouse lung tissue following administration of exogenous mitochondria by nebulizer. [Figure 5B] 13 shows images of immunohistochemical staining of mouse lung tissue following administration of exogenous mitochondria via the pulmonary artery. [Figure 6] Image of mouse lungs after 2 hours of acute lung injury (ALI) ischemia of the left lung and 24 hours of recovery. The red circle indicates the lung subjected to the ALI procedure. The right lung is indicated as R and the left lung is indicated as L. The heart (H) is shown in the center. [Figure 7A]Figure 1 is a bar graph showing pulmonary resistance in mouse lungs (n=4) subjected to 2 hours of left lung ischemia followed by 24 hours of recovery. Vehicle or mitochondria were delivered intravascularly via the left pulmonary artery (V) or by nebulizer (N). [Figure 7B] 1 is a bar graph showing elasticity in mouse lungs subjected to 2 hours of left pulmonary ischemia followed by 24 hours of recovery. Vehicle or mitochondria were delivered intravascularly via the left pulmonary artery (V) or by nebulizer (N). [Figure 8A] 1 is a bar graph showing quantification of circulating free mtDNA determined by real-time PCR for whole blood samples from BALB / cJ mice administered respiration buffer only (sham) or mitochondria (3×10 7 mitochondria in respiration buffer). [Figure 8B] 13 is an image of lung tissue stained with hematoxylin and eosin. [Figure 8C] Images of lung tissue stained with Masson's three colors. [Figure 8D] 13 is a transmission electron microscope image of lung tissue from the right lower lobe. [Figure 9A] Images showing quantification of mitochondrial uptake and biodistribution. Both are PET-microCT images of 18F-Rhodamine 6G-labeled mitochondria (1x109) delivered to the lungs of Wistar rats via injection into the pulmonary trunk. [Figure 9B] Images showing quantification of mitochondrial uptake and biodistribution. PET-microCT imaging of 18F-Rhodamine 6G-labeled mitochondria (1 × 109) delivered as an aerosol via nebulization to the lungs of Wistar rats. [Figure 10A] FIG. 11 is an immunohistochemical image (100x) demonstrating exogenous mitochondria derived from human cardiac fibroblasts delivered via vascular delivery taken up within lung tissue. [Figure 10B] FIG. 11 is an immunohistochemistry image (100x) demonstrating exogenous mitochondria from human cardiac fibroblasts delivered via aerosol uptake within lung tissue. [Figure 11A]13 is a bar graph showing the results of a pulmonary function analysis of dynamic compliance for lungs receiving mitochondria via vascular delivery. [Figure 11B] 1 is a bar graph showing the results of a pulmonary function analysis of resistance for lungs receiving mitochondria via vascular delivery. [Figure 11C] 1 is a bar graph showing the results of a pulmonary function analysis of tissue dumping for lungs receiving mitochondria via vascular delivery. [Figure 11D] 1 is a bar graph showing the results of a pulmonary function analysis of maximum inspiratory volume for lungs receiving mitochondria via vascular delivery. [Figure 11E] 13 is a bar graph showing the results of a pulmonary function analysis of maximum inspiratory pressure for lungs receiving mitochondria via vascular delivery. [Figure 12A] 13 shows the results of a pulmonary function analysis of dynamic compliance for lungs receiving mitochondria via nebulization. [Figure 12B] 1 is a bar graph showing the results of a pulmonary function analysis of resistance for lungs receiving mitochondria via nebulization. [Figure 12C] 13 is a bar graph showing the results of a pulmonary function analysis of tissue dumping for lungs receiving mitochondria via aerosol. [Figure 12D] 13 is a bar graph showing the results of a pulmonary function analysis of maximum inspiratory volume for lungs receiving mitochondria via nebulization. [Figure 12E] 13 is a bar graph showing the results of a pulmonary function analysis of maximum inspiratory pressure for lungs receiving mitochondria via nebulization. [Figure 13] Results of pulmonary function analysis, specifically representative pressure-volume loops, are shown. [Figure 14A] 13 shows hematoxylin and eosin (H&E), myeloperoxidase staining (MPO), TUNEL, and transmission electron microscopy (EM) images of lung tissue sections for lungs receiving vehicle via vascular delivery. Scale bar: 500 μm. [Figure 14B]Images showing hematoxylin and eosin (H&E), myeloperoxidase staining (MPO), TUNEL, and transmission electron microscopy (EM) images of lung tissue sections for lungs receiving mitochondria via vascular delivery. Scale bar: 500 μm. [Figure 14C] Images showing hematoxylin and eosin (H&E), myeloperoxidase staining (MPO), TUNEL, and transmission electron microscopy (EM) images of lung tissue sections for lungs receiving vehicle via nebulization. Scale bar: 500 μm. [Figure 14D] Images showing hematoxylin and eosin (H&E), myeloperoxidase staining (MPO), TUNEL, and transmission electron microscopy (EM) images of lung tissue sections for lungs receiving mitochondria via aerosol. Scale bar: 500 μm. [Figure 14E] Images showing hematoxylin and eosin (H&E), myeloperoxidase staining (MPO), TUNEL, and transmission electron microscope (EM) images of lung tissue sections for the sham group. Scale bar: 500 μm. [Figure 15A] FIG. 1 is a bar graph showing the severity of lung tissue injury at 24 hours of reperfusion for lungs receiving vehicle via vascular delivery (Vehicle V), mitochondria via vascular delivery (Mito V), and sham groups. After 2 hours of ischemia and 24 hours of reperfusion, H&E stained sections (15x) were assessed for severity of lung injury using the scoring system previously described. The worse the tissue injury, the higher the score (1-5). Severity of tissue injury analysis shows a significant reduction in inflammatory cell infiltration and interstitial congestion without signs of destruction of lung architecture in Mito V and Mito Neb lungs compared to Vehicle V and Vehicle Neb. [Figure 15B]FIG. 1 is a bar graph showing neutrophil counts at 24 hours of reperfusion for lungs receiving vehicle via vascular delivery (Vehicle V), Mitochondria via vascular delivery (Mito V), and Sham groups. After 2 hours of ischemia and 24 hours of reperfusion, H&E stained sections (15x) were assessed for severity of lung injury using the scoring system previously described. The worse the tissue injury, the higher the score (1-5). Severity of tissue injury analysis shows a significant reduction in inflammatory cell infiltration and interstitial congestion without signs of destruction of lung architecture in Mito V and Mito Neb lungs compared to Vehicle V and Vehicle Neb. [Figure 15C] Figure 1 is a bar graph showing TUNEL labeled nuclei per 100 nuclei at 24 hours of reperfusion for lungs receiving vehicle via vascular delivery (Vehicle V), Mitochondria via vascular delivery (Mito V), and Sham groups. After 2 hours of ischemia and 24 hours of reperfusion, H&E stained sections (15x) were assessed for severity of lung injury using the scoring system previously described. The worse the tissue injury, the higher the score (1-5). Severity of tissue injury analysis shows a significant reduction in inflammatory cell infiltration and interstitial congestion without signs of destruction of lung architecture in Mito V and Mito Neb lungs compared to Vehicle V and Vehicle Neb. [Figure 15D] FIG. 1 is a bar graph showing the severity of lung tissue injury at 24 hours of reperfusion for lungs receiving vehicle via nebulization (Vehicle Neb), mitochondria via vascular delivery (Mito Neb), and sham groups. After 2 hours of ischemia and 24 hours of reperfusion, H&E stained sections (15x) were assessed for severity of lung injury using the scoring system previously described. The worse the tissue injury, the higher the score (1-5). Severity of tissue injury analysis shows a significant reduction in inflammatory cell infiltration and interstitial congestion without signs of destruction of lung architecture in Mito V and Mito Neb lungs compared to Vehicle V and Vehicle Neb. [Figure 15E]FIG. 1 is a bar graph showing neutrophil counts at 24 hours of reperfusion for lungs receiving vehicle via nebulization (Vehicle Neb), Mitochondria via vascular delivery (Mito Neb), and Sham groups. After 2 hours of ischemia and 24 hours of reperfusion, H&E stained sections (15x) were assessed for severity of lung injury using the scoring system previously described. The worse the tissue injury, the higher the score (1-5). Severity of tissue injury analysis shows a significant reduction in inflammatory cell infiltration and interstitial congestion without signs of destruction of lung architecture in Mito V and Mito Neb lungs compared to Vehicle V and Vehicle Neb. [Figure 15F] Figure 1 is a bar graph showing TUNEL labeled nuclei per 100 nuclei at 24 hours of reperfusion for lungs receiving vehicle via nebulization (Vehicle Neb), Mito via vascular delivery (Mito Neb), and Sham groups. After 2 hours of ischemia and 24 hours of reperfusion, H&E stained sections (15x) were assessed for severity of lung injury using the scoring system previously described. The worse the tissue injury, the higher the score (1-5). Severity of tissue injury analysis shows a significant reduction in inflammatory cell infiltration and interstitial congestion without signs of destruction of lung architecture in Mito V and Mito Neb lungs compared to Vehicle V and Vehicle Neb. [Figure 15G] Figure 1 is a bar graph showing the wet to dry weight ratio as a percentage at 24 hours of reperfusion for lungs receiving vehicle via vascular delivery (Vehicle V), mitochondria via vascular delivery (Mito V), vehicle via nebulization (Vehicle Neb), mitochondria via nebulization (Mito Neb), and sham groups. After 2 hours of ischemia and 24 hours of reperfusion, H&E stained sections (15x) were assessed for severity of lung injury using the scoring system previously described. The worse the tissue injury, the higher the score (1-5). Severity of tissue injury analysis shows a significant reduction in inflammatory cell infiltration and interstitial congestion without signs of destruction of lung architecture in Mito V and Mito Neb lungs compared to Vehicle V and Vehicle Neb. [Figure 16]Quantitative results from BAL cytokine analysis are shown and all values are expressed as mean±standard error of the mean (SEM), n=4 for all groups. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0046] The present disclosure relates to compositions containing mitochondria (e.g., viable and functional mitochondria), methods of preparing and using the compositions, and devices for administering the compositions to the airways of a subject. The present disclosure shows that mitochondria can be effectively administered to a subject via the airways, and that delivery of an aerosolized form of a composition comprising mitochondria to the airways is unexpectedly as effective as intra-arterial administration.
[0047] The present disclosure also provides methods by which pharmaceutical compositions containing viable and functional mitochondria can be safely and reliably produced. Pharmaceutical compositions as described herein can have increased therapeutic value, increased commercial value, and lower production costs per therapeutic dose.
[0048] In one aspect, the present disclosure provides a method for delivering mitochondria or complex mitochondrial drugs to cells lining and surrounding airways. Such pharmaceutical compositions can be taken up by cells, and once localized in the cells, the mitochondria can impart one or more biological effects. These biological effects include, but are not limited to, producing energy for cells via respiration, producing ATP (i.e., converting ADP to ATP), regulating cell metabolism, initiating the citric acid cycle or the Krebs cycle, producing heat, storing calcium ions, signaling via mitochondrial reactive oxygen species, regulating membrane potential, inducing apoptotic programmed cell death, participating in calcium signaling (e.g., calcium-induced apoptosis), synthesizing heme and / or steroids, and initiating hormone signaling.
[0049] Aerosolized Composition The present disclosure provides an aerosolized composition comprising isolated mitochondria and / or complex mitochondrial drugs. The present disclosure shows that cellular organelles (e.g., mitochondria) in the aerosolized composition or in the form of an aerosol can remain viable and functional, and thus can be effectively administered to the airways of a subject.
[0050] As used herein, the term "aerosol" refers to a suspension of fine particles or liquid droplets in a carrier gas. As used herein, the term "aerosolization" refers to the process or behavior of converting a composition into the form of an aerosol. An aerosolized composition includes a plurality of particles (e.g., liquid droplets, solid particles, liquid droplets, or hydrogel particles). In some embodiments, the particles have a size (e.g., diameter) of about or less than 500 nm, 600 nm, 700 nm, 800 nm, 900 nm, 1 μm, 2 μm, 3 μm, 4 μm, 5 μm, 6 μm, 7 μm, 8 μm, 9 μm, 10 μm, 20 μm, 30 μm, 40 μm, 50 μm, 60 μm, 70 μm, 80 μm, 90 μm, 100 μm, 200 μm, 300 μm, 400 μm, 500 μm, 600 μm, 700 μm, 800 μm, 900 μm, or 1000 μm. In some embodiments, the particles have a size (e.g., diameter) of about or greater than 500 nm, 600 nm, 700 nm, 800 nm, 900 nm, 1 μm, 2 μm, 3 μm, 4 μm, 5 μm, 6 μm, 7 μm, 8 μm, 9 μm, 10 μm, 20 μm, 30 μm, 40 μm, 50 μm, 60 μm, 70 μm, 80 μm, 90 μm, 100 μm, 200 μm, 300 μm, 400 μm, 500 μm, 600 μm, 700 μm, 800 μm, 900 μm, or 1000 μm. In some embodiments, the particles have a size (e.g., diameter) of 500 nm to 10 μm, 500 nm to 100 μm, 1 μm to 10 μm, 1 μm to 100 μm, 5 μm to 100 μm, 10 μm to 100 μm, or 1 μm to 500 μm. As used herein, the term "diameter" refers to the length of the longest straight line segment having both endpoints on the surface of the particle.
[0051] In some embodiments, the aerosolized composition comprises particles (e.g., droplets) having different sizes. In some embodiments, about or at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of the particles have a size (e.g., diameter) of 500 nm to 10 μm, 500 nm to 100 μm, 1 μm to 10 μm, 1 μm to 100 μm, 5 μm to 100 μm, 10 μm to 100 μm, or 1 μm to 500 μm.
[0052] In some embodiments, the particles in the aerosolized composition can have a median size (e.g., median diameter) of about or less than 500 nm, 600 nm, 700 nm, 800 nm, 900 nm, 1 μm, 2 μm, 3 μm, 4 μm, 5 μm, 6 μm, 7 μm, 8 μm, 9 μm, 10 μm, 20 μm, 30 μm, 40 μm, 50 μm, 60 μm, 70 μm, 80 μm, 90 μm, 100 μm, 200 μm, 300 μm, 400 μm, 500 μm, 600 μm, 700 μm, 800 μm, 900 μm, or 1000 μm. In some embodiments, the particles can have a median size (e.g., median diameter) of about or greater than 500 nm, 600 nm, 700 nm, 800 nm, 900 nm, 1 μm, 2 μm, 3 μm, 4 μm, 5 μm, 6 μm, 7 μm, 8 μm, 9 μm, 10 μm, 20 μm, 30 μm, 40 μm, 50 μm, 60 μm, 70 μm, 80 μm, 90 μm, 100 μm, 200 μm, 300 μm, 400 μm, 500 μm, 600 μm, 700 μm, 800 μm, 900 μm, or 1000 μm. In some embodiments, the particles can have a median size (e.g., median diameter) of 500 nm to 10 μm, 500 nm to 100 μm, 1 μm to 10 μm, 1 μm to 100 μm, 5 μm to 100 μm, 10 μm to 100 μm, or 1 μm to 500 μm. As used herein, the term "median size" refers to a median size (e.g., diameter) as determined on a volumetric basis. When the term median size is used, it is understood to describe a particle size that divides a population in half such that 50% of the population is larger or smaller than this size on a volumetric basis.
[0053] Aerosolized compositions can be produced by various devices known in the art.Exemplary devices that can convert compositions into aerosol form before administration include, for example, nebulizers, vaporizers, nasal sprays, atomizers, soft mist atomizers, jet nebulizers, ultrasonic nebulizers, pressurized metered dose inhalers, breath-activated pressurized metered dose inhalers, or vibrating mesh devices.These devices can use various carrier gases, including, for example, oxygen, air, nitrogen, or compressed air.
[0054] The composition before aerosolization can include one or more pharma- ceutically acceptable carriers. The pharma- ceutically acceptable carriers can be compounds or compositions useful for facilitating the storage, stability, administration, cell targeting and / or delivery of mitochondria and / or complex mitochondrial drugs. The pharma- ceutically acceptable carriers include, but are not limited to, suitable vehicles, diluents, solvents, excipients, pH adjusters, osmolytes, salts, colorants, rheology modifiers, lubricants, coatings, fillers, antifoaming agents, polymers, hydrogels, surfactants, emulsifiers, adjuvants, preservatives, phospholipids, fatty acids, mono-, di- and triglycerides and their derivatives, waxes, oils and water. In some embodiments, the isolated mitochondria and / or complex mitochondrial drugs are suspended in water, saline, buffer, respiratory buffer or sterile mitochondrial buffer for in vivo delivery. Pharmaceutically acceptable salts, buffers or buffer systems, including but not limited to saline, phosphate buffer, phosphate buffered saline (PBS) or respiratory buffer, can be included in the compositions described herein. Vehicles capable of facilitating delivery to cells in vivo, such as liposomes, can be utilized to facilitate delivery of mitochondria or complex mitochondrial drugs to target cells.
[0055] Exemplary buffers include, but are not limited to, respiratory buffers (e.g., 250 mmol / L sucrose, 20 mmol / L K+-HEPES buffer (pH 7.2), 0.5 mmol / L K+-EGTA (pH 8.0)). Exemplary osmolytes include, but are not limited to, trehalose, sucrose, mannose, glycine, proline, glycerol, mannitol, sorbitol, betaine, and sarcosine.
[0056] Isolated mitochondria and complex mitochondrial drugs Mitochondria for use in the methods described herein can be isolated or provided from any source, for example, isolated from cultured cells or tissues. Exemplary cells include, but are not limited to, muscle tissue cells, cardiac fibroblasts, cultured cells, HeLa cells, prostate cancer cells, yeast, blood cells, cultured cells, and any mixtures thereof, among others. Exemplary tissues include, but are not limited to, liver tissue, skeletal muscle, heart, brain, blood, and adipose tissue (e.g., brown adipose tissue). Mitochondria can be isolated from cells of autologous, allogeneic, and / or xenogeneic sources. In some examples, mitochondria are isolated from cells with genetic modifications, for example, cells with modified mtDNA or modified nuclear DNA.
[0057] Mitochondria can be isolated from cells or tissues by methods known to those skilled in the art. In some embodiments, a tissue or cell sample is collected and then homogenized. After homogenization, mitochondria are isolated by repeated centrifugation. Alternatively, the cell homogenate can be filtered through a nylon mesh filter. Exemplary methods for isolating mitochondria are described, for example, in McCully et al, Injection of isolated mitochondria during early reperfusion for cardioprotection, Am J Physiol 296, H94-H105. PMC2637784 (2009), Frezza et al., Organelle isolation: functional mitochondria from mouse liver, muscle and cultured filroblasts. Nature protocols, 2(2), 287-295 (2007), US Patent Publication No. 2018 / 0057610, and US Patent Publication No. 2018 / 0057610, each of which is incorporated by reference.
[0058] Mitochondria for treatment can be isolated from autologous, allogeneic and xenogeneic cell or tissue.In some cases, mitochondria are collected from the cultured cells or tissue of a subject, and these mitochondria are administered back to the same subject.In some other cases, mitochondria are collected from the cultured cells or tissue of a second subject, and these mitochondria are administered to the first subject.In some cases, mitochondria are collected from the cultured cells or tissue of different species (e.g., mouse, pig, yeast).
[0059] The disclosure also provides compositions that include complex mitochondrial drugs, which include mitochondria in physical association with an agent, such as a therapeutic agent, a diagnostic agent, and / or an imaging agent.
[0060] The therapeutic agent may be any agent that has therapeutic or preventive use. Exemplary therapeutic agents include, for example, therapeutic agents for ischemia-related disorders, cytotoxic agents for treating cancer, among others. In some examples, mitochondria can deliver therapeutic agents to specific cells, for example, tumor cells. The therapeutic agent may be, for example, an intracellular inhibitor, inactivator, toxin, arresting agent, and / or cytostatic / cytotoxic agent that, once inside the cell, inhibits, destroys, stops, modifies, and / or changes the cell such that it can no longer function normally and / or survive. The therapeutic agent may be an agent for restoring proper function of the cell, for example, a DNA vector for gene therapy. The therapeutic agent may be, for example, an inorganic or organic compound, a small molecule (less than 500 daltons) or large molecule, a proteinaceous molecule such as a peptide, polypeptide, protein, post-translationally modified protein, or antibody, or a nucleic acid molecule such as a double-stranded DNA, single-stranded DNA, double-stranded RNA, single-stranded RNA, or triple-helical nucleic acid molecule. In some embodiments, the therapeutic agent can be a natural product derived from any known organism (e.g., from an animal, plant, bacteria, fungus, protist, or virus) or a library of synthetic molecules. In some embodiments, the therapeutic agent can be a monomeric or polymeric compound. Some exemplary therapeutic agents include cytotoxic drugs, DNA vectors, small interfering RNA (siRNA), microRNA (miRNA), reactive peptides, nanoparticles, microspheres, and fluorescent molecules.
[0061] A diagnostic agent is an agent that has diagnostic use. Because mitochondria deliver diagnostic agents into cells, in some embodiments diagnostic agents can be designed to determine conditions within the cells, such as pH and oxidative stress within the cells.
[0062] Imaging agents are agents employed for use in imaging techniques. Techniques or types include, but are not limited to, X-ray, computed tomography (CT), magnetic resonance imaging (MRI), scintigraphy, fluorescence, ultrasound, and the like. Imaging agents can be fluorescent and / or radioactive. In some embodiments, imaging agents can also be diagnostic agents. Exemplary imaging agents include MitoTracker fluorophores (Thermo Fisher Scientific Inc.), CellLight® RFP, BacMam2.0 (Thermo Fisher Scientific Inc.), pH-sensitive pHrodo fluorescent dyes (Thermo Fisher Scientific Inc.), 18 F-Rhodamine 6G, 18 These include, but are not limited to, F-labeled rhodamine B, magnetic iron oxide nanoparticles, and gold- and platinum-based nanoparticles.
[0063] As discussed above, a complex mitochondrial drug includes a mitochondria and an agent that are in direct and / or indirect physical contact with each other. For example, the agent can be linked to the mitochondria, bound to the mitochondria, embedded in the mitochondrial membrane, or fully or partially enclosed in the mitochondria. In some examples, the drug can be covalently bound to the mitochondria. In some examples, the agent is directly linked to a component of the mitochondrial membrane via a covalent bond (e.g., a carboxamide bond and a disulfide bond) or indirectly linked to a linker (e.g., a peptide linker) or another covalently bound agent. In other examples, the agent can be non-covalently bound to the mitochondria, for example, via hydrophobic interactions, van der Waals interactions, and / or electrostatic interactions.
[0064] In some embodiments, a complex mitochondrial drug can include two or more different types of agents, e.g., two different types of therapeutic agents, three different types of imaging agents, one therapeutic agent and one imaging agent, a therapeutic agent and a diagnostic agent, etc. Those skilled in the art will recognize that some variations are possible.
[0065] One particularly useful linker for linking mitochondria and active agent provides sustained release of active agent upon injection.This can be achieved, for example, by using hydrazone functional group.For example, hydrazone is formed to covalently bind active agent to a component on mitochondrial membrane.Once this conjugated mitochondrial drug is taken up by cells, pH change leads to hydrolysis of hydrazone, releasing the bound active agent into the cell.
[0066] In some embodiments, therapeutic, diagnostic, and / or imaging agents can be linked to the outer mitochondrial membrane using functionalized surface chemistries. In some cases, heterobifunctional chemistries can link therapeutic, diagnostic, and / or imaging agents to the mitochondrial surface, and once the heterobifunctional chemistry is internalized, these agents can be released via interaction with intracellular esterases (e.g., via interaction with acetoxymethyl esters) or via UV or near-infrared light activation strategies. UV and near-infrared light activation strategies are described, for example, in Zhou et al., "Progress in the Field of Constructing Near-Infrared Light-Responsive Drug Delivery Platforms," Journal of Nanoscience and Nanotechnology 16.3(2016):2111-2125; Bansal et al., "Photocontrolled nanoparticle delivery systems for biomedical applications," Accounts of chemical research 47.10(2014):3052-3060; Barhoumi et al., "Ultraviolet light-mediated drug delivery: Principles, applications, and challenges," Journal of Controlled Release 219(2015):31-42; and U.S. Patent Application Publication No. 2018 / 0057610, each of which is incorporated by reference in its entirety.
[0067] In some cases, those skilled in the art will recognize that the compositions described herein can contain more than one type of complex mitochondrial drug.For example, compositions containing mitochondria, each mitochondria is essentially associated with multiple types of agents.Also included are compositions containing mitochondria, each mitochondria is paired with only one type of agent, but the composition contains a mixture of mitochondria / agent pairings.
[0068] Methods for preparing complex mitochondrial drugs One of skill in the art will recognize that an agent can be linked to mitochondria in a number of ways, for example, by being attached to the mitochondria, partially or completely embedded within the mitochondrial membrane, trapped within the mitochondria, or encapsulated within the mitochondria.
[0069] Without intending to be bound by any theory or any particular approach, it is believed that the outer membrane of mitochondria is adhesive and therefore particularly suitable for combination with various agents. In some embodiments, the pharmaceutical agent can be attached to the outer membrane of mitochondria simply by incubation. For example, an effective amount of the pharmaceutical agent can be thoroughly mixed with the isolated mitochondria in a buffer, e.g., a respiratory buffer, at a temperature preferred for the isolated mitochondria, e.g., 0°C to 26°C, 0°C to 4°C, or about 0°C, 4°C, 26°C. This procedure is useful for attaching an effective amount of the pharmaceutical agent (e.g., nanoparticles, DNA vectors, RNA vectors) to the mitochondria.
[0070] In some embodiments, organic cations (e.g., rhodamine and tetramethylrosamine) are easily sequestered by functioning mitochondria due to the electrical potential on the mitochondrial membrane. Healthy mitochondrial membranes maintain a potential difference between the inside and outside of the organelle, referred to as the membrane potential. This membrane potential is a direct result of mitochondrial functional processes and can be lost if mitochondria are not functioning properly. Lipid-soluble cations are sequestered by mitochondria as a result of their positive charge and their solubility in both the inner membrane lipids and matrix aqueous space. Similarly, in some other embodiments, anions can be attached to the outer membrane of mitochondria due to their negative charge. To link mitochondria with these pharmaceuticals, an effective amount of pharmaceutical should be thoroughly mixed with isolated mitochondria in a buffer, e.g., a respiratory buffer, at a temperature preferred for isolated mitochondria, e.g., about 0°C or 4°C.
[0071] Therapeutic, diagnostic, and / or imaging agents can be linked to phospholipids, peptides, or proteins on the mitochondrial membrane via chemical bonds. For example, molecules including fluorophores (pHrodo Red (Thermo Fisher Scientific, Inc.)) and metal particles (e.g., 30 nm magnetic iron oxide nanoparticles (Sigma)) can be covalently attached to exposed amine groups on proteins and peptides exposed on the outer membrane of intact mitochondria using succinimidyl ester conjugates. These reactive reagents react with unprotonated aliphatic amine groups, including the amine termini of proteins and the ε-amino groups of lysine residues, to create stable carboxamide bonds. In another example, pharmaceuticals, such as MitoTracker® Orange CMTMRos (Invitrogen, Carlsbad, Calif., now Thermo-Fisher Scientific, Cambridge, Mass.), are mixed with functional mitochondria, where they are oxidized and then react with thiols on proteins and peptides on the mitochondria to form complexes.
[0072] There are numerous reactive chemical moieties available for attaching therapeutic, diagnostic, and / or imaging agents to the surface of mitochondria (eg, carboxylic acids, functionalized amines, etc.).
[0073] The agent can be attached to either the outer or inner mitochondrial membrane via protein linkage, amine linkage or other attachment methods. Alternatively, or in addition, the agent can be attached to the mitochondrial membrane via hydrophobic, van der Waals, and / or electrostatic interactions.
[0074] In many instances, the therapeutic, diagnostic and imaging agents can simply be mixed with the isolated mitochondria and incubated in a buffer (e.g., a respiration buffer) for a sufficient time (e.g., several minutes, 5 minutes, 10 minutes, or 1 hour) under preferred conditions (e.g., 0°C-26°C, 0°C-4°C, or about 0°C, 4°C, 26°C, pH 7.2-8.0).
[0075] Exemplary methods for preparing complex mitochondrial drugs are described in McCully et al, Injection of isolated mitochondria during early reperfusion for cardioprotection, Am J Physiol 296, H94-H105. PMC2637784 (2009), and Masuzawa et al, Transplantation of autologously derived mitochondria protects the heart from ischemia-reperfusion injury, Am J Physiol 304, H966-982. PMC3625892 (2013), as well as U.S. Patent Publication No. 20180057610. Each of the foregoing is incorporated by reference in its entirety.
[0076] Treatment The methods described herein include methods for the treatment of various diseases (e.g., pulmonary disorders, respiratory disorders), ischemia-reperfusion injury, and various other diseases described herein. In general, the methods include administering to a subject in need of, or determined to be in need of, such treatment a therapeutically effective amount of a composition comprising an isolated mitochondrial or complex mitochondrial drug as described herein. In some embodiments, the composition is administered via the airway.
[0077] As used in this context, "treating" means improving at least one symptom of the disorder (e.g., dyspnea, hyperventilation, low blood oxygen levels, pulmonary insufficiency, respiratory failure, cardiac failure (e.g., right heart failure)). In some embodiments, the treatment results in improved pulmonary function (e.g., increased blood oxygen levels, reduced resistance, reduced elastance). In some embodiments, the methods described herein can be used to treat pulmonary fibrosis, pulmonary infection (e.g., due to coronavirus), asthma, chronic obstructive pulmonary disease, pulmonary embolism, lung cancer, pulmonary hypertension, or lymphangioleiomyomatosis. In some embodiments, the methods described herein can be used to treat pneumonia.
[0078] The terms "subject" and "patient" are used interchangeably throughout this specification and describe an animal, human or non-human, to whom treatment with the methods of the invention is provided. Both veterinary and non-veterinary applications are contemplated by the present invention.
[0079] The human patient may be an adult or a child, such as a newborn. For example, the human subject may be at least or about 60 years old, e.g., at least about 65, 70, 75 years old, or at least or about 80 years old. The human subject may be less than or about 18 years old, e.g., 15, 10, 9, 8, 7, 6, 5, 4, 3, 2 years old, or less than or about 1 year old.
[0080] In addition to humans, subjects can include non-humans, such as, but are not limited to, mice, rats, hamsters, guinea pigs, rabbits, ferrets, cats, dogs, and primates, including, but not limited to, non-human primates (e.g., monkeys, chimpanzees, gorillas, etc.), rodents (e.g., rats, mice, gerbils, hamsters, ferrets, rabbits), lagomorphs, pigs (e.g., piglets, miniature pigs), horses, dogs, cats, cows, and other domestic, farm, and zoo animals.
[0081] Administration of the compositions described herein can be accomplished by a variety of means, for example, intravenous, intradermal, subcutaneous, transdermal (topical), transmucosal, rectal administration, intranasal administration, intranasal drops, insufflation (e.g., nasal spray), inhalation (through the nose or mouth), intrapulmonary administration, intratracheal administration, intraperitoneal injection, infusion, or any combination thereof. In some embodiments, the compositions are administered via the respiratory tract.
[0082] In one aspect, isolated mitochondria and / or complex mitochondrial drugs can be delivered to the lungs or heart to reduce stunning and allow organ withdrawal from a surgical procedure (e.g., lung or heart surgery). In some embodiments, the method includes administering isolated mitochondria and / or complex mitochondrial drugs via the airway.
[0083] In one aspect, isolated mitochondria and / or complex mitochondrial drugs can be delivered to the ear, eye, skin (e.g., to reduce wrinkles), or head (e.g., for alopecia).
[0084] The compositions described herein can be administered to a subject as a one-time treatment or, alternatively, as multiple treatments, e.g., as a course of treatment continuing for about 1, 2, 5, 8, 10, 20, 30, 50, or 60 days, intermittently or continuously for a year, indefinitely, or until a medical professional determines that administration of the mitochondrial or complex mitochondrial drug is no longer necessary.
[0085] The isolated mitochondria and / or complex mitochondrial drugs can be administered to a subject as a single dose or in multiple doses delivered every 5 minutes or every 12-24 hours. In some embodiments, the isolated mitochondria or complex mitochondrial drugs can be administered to a subject every 5-10 minutes (e.g., every 5 minutes, every 10 minutes).
[0086] It is noted that in some cases, the effect of mitochondria depends on the length of time between the time of isolation and the time of use. Thus, in some examples, the mitochondria are freshly isolated and viable. The mitochondria or complex mitochondrial drug can be administered to a subject within about 5 minutes, about 10 minutes, about 20 minutes, about 30 minutes, about 40 minutes, about 50 minutes, about 60 minutes, about 70 minutes, about 80 minutes, about 90 minutes, about 100 minutes, about 110 minutes, about 120 minutes after isolating the mitochondria. In some examples, the mitochondria or complex mitochondrial drug is administered to a subject within about 5 minutes, about 10 minutes, about 20 minutes, about 30 minutes, about 40 minutes, about 50 minutes, about 60 minutes, about 70 minutes, about 80 minutes, about 90 minutes, about 100 minutes, about 110 minutes, about 120 minutes after starting the mitochondria isolation process. The mitochondria and / or complex mitochondrial drugs can, in some cases, be stored for a short period of time (eg, about or at least 10 minutes, 20 minutes, 30 minutes, 40 minutes, 50 minutes, or 60 minutes) prior to use.
[0087] It is also noted that in some cases, freeze-thawed mitochondria are not viable and are not effective in certain treatments described herein, such as treating ischemia / reperfusion injury, and therefore, in some cases, the mitochondria are not freeze-thawed after isolation from tissues and / or cells.
[0088] In some embodiments, the compositions and methods described herein can be used to treat disorders associated with the lungs, ears, eyes, skin, and scalp. For example, the compositions and methods described herein can be used to treat cancer, wrinkles (e.g., wrinkles on the skin), or alopecia. In some cases, the compositions and methods described herein are for enhancing the function of various tissues and organs (e.g., lungs, ears, eyes, skin).
[0089] Administration via the airways Mucus lining the pulmonary epithelium (1-10 μm thick) and surfactant lining the alveoli (0.1-0.2 μm thick) constitute a physical barrier to pulmonary absorption of foreign particles. In addition, membrane-bound (epithelial and endothelial) and intracellular (macrophages, lymphocytes, neutrophils and mast cells) proteases and peptidases readily degrade administered peptides and proteins (Agu et al, ``The lung as a route for systemic delivery of therapeutic proteins and peptides.'' Respiratory research 2.4(2001):198). Pulmonary macrophages have also been shown to secrete or release short-lived peroxidases, inflammatory and immunomodulatory mediators (including granulocyte colony-stimulating factor, interleukins, leukotrienes and proteases), as well as other molecules as part of host defense mechanisms.
[0090] Nevertheless, the present disclosure shows that administering a composition comprising mitochondria or a complex mitochondrial drug via the airways can effectively promote lung function, reduce lung resistance, reduce lung elastance, reduce ischemic area, and / or reduce edema and cell damage in the lungs.
[0091] The compositions described herein can be administered via the airways by a variety of means, for example, intranasal administration, intranasal instillation, insufflation (e.g., nasal spray), inhalation (through the nose or mouth), intrapulmonary administration, intratracheal administration, or any combination thereof. As used herein, the term "intranasal instillation" refers to a procedure in which a therapeutic agent is delivered directly to the nose and nasal membranes, where a portion of the therapeutic agent can pass through the trachea and be delivered to the lungs.
[0092] Therapeutic agents sometimes cannot be effectively delivered to the target site of the lung (e.g., bronchioles or alveoli) via airway administration because the lung function that requires treatment may be limited. In these cases, an agent that can clear the airway can be administered to the subject first. In some embodiments, these agents can induce bronchial dilation and / or muscular vasodilation. Such agents include, but are not limited to, β2-adrenergic receptor agonists, anticholinergic agents, and corticosteroids. In some embodiments, agents for treating asthma can be used.
[0093] Pharmaceutical compositions suitable for administration via the respiratory tract can include, for example, liquid solutions, aqueous solutions (if water soluble), or dispersions, etc. In some embodiments, these compositions can include one or more surfactants.
[0094] As used herein, the term "airways" refers to the air passages from the nose to the alveoli, including the nose, throat, pharynx, larynx, trachea, bronchi, and any portion of the lungs. In some embodiments, the compositions are administered to the lungs or any portion of the respiratory system.
[0095] In some embodiments, the composition can be administered to a subject by a delivery system capable of converting the composition into an aerosol form, such as a nebulizer, vaporizer, nasal spray, atomizer, soft mist atomizer, jet nebulizer, ultrasonic nebulizer, pressurized metered dose atomizer, breath-activated pressurized metered dose atomizer, or vibrating mesh device. As used herein, the term "nebulizer" refers to a device for administering a composition in the form of a spray or dry powder that is inhaled (either naturally or mechanically forced into the lungs) through the nose or oral cavity. In some embodiments, the atomizer includes, for example, a passive or active ventilator (mechanical with or without an endotracheal tube), a nebulizer, a dry powder atomizer, a metered dose atomizer, and a pressurized metered dose atomizer. Once mitochondria are deposited or localized near a cell, a subset of mitochondria can be taken up by the cell.
[0096] In some embodiments, the device can use air (e.g., oxygen, compressed air) or ultrasonic power to break down solutions and suspensions into small aerosol particles (e.g., droplets) that can be inhaled directly through the mouthpiece of the device. In some embodiments, the device uses a mesh / membrane with laser-drilled holes (e.g., 1000-7000 holes) that vibrates on top of a liquid reservoir, thereby forcing a mist of very fine droplets through the holes.
[0097] The delivery system can also include a unit dose delivery system. The volume of solution or suspension delivered per dose can be from about 5 to about 2000 microliters, from about 10 to about 1000 microliters, or from about 50 to about 500 microliters. The delivery system for these various dosage forms can be a dropper bottle, a plastic squeeze unit, an atomizer, a nebulizer, or a pharmaceutical aerosol, either in a unit dose or multi-dose package.
[0098] In some embodiments, the device is a small, hard bottle with a metered dose sprayer attached. The metered dose can be delivered by drawing the composition into a chamber of a defined volume, which has an opening and an aerosol formulation sized to aerosolize the liquid in the chamber by forming a spray when compressed. The chamber is compressed to administer the composition. In one particular device, the chamber is a piston device. Such devices are commercially available.
[0099] Alternatively, a squeeze bottle can be used that has an aperture or opening dimensioned to aerosolize the aerosol formulation by forming a spray upon squeezing. The opening is usually found at the top of the bottle, and the top is generally tapered to fit partially within the nasal cavity for efficient administration of the aerosol formulation. Preferably, the nasal sprayer is capable of providing a metered amount of the aerosol formulation for administration of a measured dose of a therapeutic agent.
[0100] In some embodiments, the aerosolization of the liquid formulation for inhalation into the lungs includes a propellant.The propellant can be any propellant commonly used in the art.Specific non-limiting examples of such useful propellants are chlorofluorocarbons, hydrofluorocarbons, hydrochlorofluorocarbons, or hydrocarbons, including trifluoromethane, dichlorodifluoromethane, dichlorotetrafluoroethanol, and 1,1,1,2-tetrafluoroethane, or combinations thereof.
[0101] The present disclosure also provides aerosol formulations and dosage forms for use in treating subjects suffering from various pulmonary diseases. Generally, such dosage forms contain a therapeutic agent in a pharma- ceutically acceptable diluent. The pharma-ceutically acceptable diluents in such aerosol formulations include, but are not limited to, sterile water, saline, buffered saline, dextrose solution, and the like. In certain embodiments, the diluent that can be used in the present invention or pharmaceutical formulation is phosphate buffered saline or buffered saline, generally in the range of pH 7.0-8.0 (e.g., pH 7.4), or water.
[0102] The aerosol formulation may also optionally contain pharma- ceutically acceptable carriers, diluents, solubilizing or emulsifying agents, surfactants, and excipients.
[0103] The formulation may include a carrier. The carrier is a polymer that is soluble in the circulatory system and physiologically acceptable, meaning that one skilled in the art would accept the carrier as part of a treatment regimen and injected into a patient. The carrier is preferably relatively stable in the circulatory system with an acceptable plasma half-life for clearance. Such polymers include, but are not limited to, soybean lecithin, oleic acid, and sorbitan trioleate.
[0104] The formulation may also include other agents useful for maintaining pH, stabilizing the solution, or regulating osmolality. Examples of agents include, but are not limited to, salts, such as sodium chloride or potassium chloride, and carbohydrates, such as glucose, galactose, or mannose.
[0105] The present disclosure further contemplates an aerosol formulation comprising a composition as described herein and another therapeutically effective agent.
[0106] In some embodiments, the compositions can be administered intravascularly. The blood can carry the mitochondria or complex mitochondrial drugs to a target site, such as an organ, tissue, or injury site. For example, the pulmonary blood vessels (e.g., pulmonary veins) can carry the mitochondria or complex mitochondrial drugs to the lungs. In some cases, the compositions described herein can be used to improve lung, ear, eye, and skin function.
[0107] In some embodiments, the compositions are administered by oral or nasal respiratory routes for local or systemic effects. Compositions in medicamentously acceptable solvents can be nebulized by use of inert gases. Nebulized solutions can be inhaled directly from the nebulizing device, or the nebulizing device can be attached to a face mask or intermittent positive pressure breathing machine. Solution, suspension, or powder compositions can be administered orally or nasally from a device that delivers the formulation in an appropriate manner. For administration by inhalation, the compositions can be delivered in the form of an aerosol spray from a pressurized container or dispenser containing a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer. Such methods include those described in U.S. Pat. No. 6,468,798, U.S. Pat. No. 6,695,227, U.S. Pat. No. 7,431,222, and U.S. Patent Publication No. 2005 / 0224608, each of which is incorporated herein by reference in its entirety.
[0108] Thus, in some embodiments, the aerosol composition can be administered to the airways, lungs, ears, eyes, nasal passages, rectum, skin, and head, hi some embodiments, the composition is delivered to the lungs, nasal passages, rectum, intestines, skin, and eyes to treat cancer or tumors at these sites.
[0109] In some embodiments, the composition is administered via a metered dose spray, squeeze bottle, pressurized metered dose sprayer, respirator, or face mask and tent. Aerosol delivery systems such as pressurized metered dose sprayers and dry powder sprayers are disclosed in Newman, SP, Aerosols and the Lung, Clarke, SW and Davia, D. editors, pp. 197-22, the entirety of which is incorporated herein by reference. The subject can also inhale the composition via a respirator, which will be set to a flow rate based on the patient's comfort and needs. The flow rate is determined by pulmonary graphics (i.e., respiratory rate, tidal volume, etc.). The composition can also be prepared to allow inhalation by the subject using a face mask or tent. In certain cases, the composition can be packaged and administered in a metered dose in a portable device (e.g., a portable nebulizer device), for example, to allow intermittent treatment of recipients who are not in a hospital environment. Different concentrations of the composition can be packaged in the container.
[0110] A convenient way to effectively deliver the composition to the alveoli is to select a nebulizer that produces sufficiently small particles (e.g., particles having an average particle size of less than 5.0 microns (μm), more preferably particles having an average particle size of about 0.2 to about 4.0 μm, and most preferably particles having an average particle size of about 0.2 to about 2 μm). Instead of selecting a small average particle size to achieve substantial alveolar deposition, a very large dose of the composition can be administered with a larger average particle size. In such an approach, if the particular composition is not too irritating at the required dose, it is beneficial to have a sufficient number of particles in the total population with a diameter in the range of 0.5 to about 5 μm to allow intra-alveolar deposition. For proximal airway delivery, the average particle size may be larger. For example, a suitable average particle size may generally be less than about 15 μm, e.g., about 4 μm to about 15 μm, e.g., about 5 μm to about 10 μm. The composition can be aerosolized by any suitable method. For use in humans or other primates, aerosols can be generated using a medical nebulizer system that delivers the aerosol through a mouthpiece, face mask, or the like, from which the subject can draw the aerosol into the lungs. A variety of nebulizers are known in the art and can be used in the methods described herein. See, for example, U.S. Pat. Nos. 4,268,460, 4,253,468, 4,046,146, 3,826,255, 4,649,911, and 4,510,829, each of which is incorporated herein by reference in its entirety. The choice of nebulizer system will depend on whether alveolar delivery or airway delivery (i.e., trachea, primary bronchi, secondary bronchi, tertiary bronchi, etc.) is desired.
[0111] Examples of nebulizers useful for alveolar delivery include the Acom1 nebulizer and the Respirgard II™ nebulizer system, both available from Marquest Medical Products, Inc., Englewood, Colorado. Other commercially available nebulizers for use with the present invention include the UltraVent™ nebulizer available from Mallinckrodt, Inc., Maryland Heights, Missouri, Wright nebulizer (Wright, BM, Lancet (1958) 3:24-25), and DeVilbiss nebulizer (Mercer et al, Am. Ind. HYR. Assoc. J. (1968) 29:66-78; TT Mercer, Chest (1981) 80:6 (Sup) 813-817). Nebulizers useful for airway delivery include those typically used in the treatment of asthma. Such nebulizers are also commercially available. One of skill in the art can determine the usefulness of a particular nebulizer by measuring the average particle size generated thereby, for example, using a 7-stage Mercer cascade impactor (Introx Products, Albuquerque, NM).
[0112] The total amount of the composition delivered to the subject will depend on several factors, including the total amount aerosolized, the type of nebulizer, particle size, the breathing pattern of the subject, the severity of the pulmonary disease, and the concentration in the aerosolized solution, as well as the length of the inhalation therapy. The amount of the composition measured in the alveoli may be substantially less than would be expected from the amount of the composition present in the aerosol, because most of the composition may be exhaled by the subject or trapped on the inner surface of the nebulizer device.
[0113] Those skilled in the art can easily design effective protocols, especially when the particle size of the aerosol is optimized. In some cases, it is useful to administer higher doses when treating more severe conditions. If necessary, treatment can be repeated on a case-by-case basis, depending on the results achieved. When repeating treatment, the mammalian host can be monitored to ensure that there is no adverse immune response to the treatment. The frequency of treatment depends on many factors, such as the amount of composition administered per dose, as well as the health and medical history of the subject. As used herein, the "atomized amount" or "aerosolized amount" of a composition refers to the amount that actually leaves the device as an aerosol, i.e., the amount that is placed in the device, minus the amount that is retained in the reservoir and on the inner surface of the device at the end of the treatment session.
[0114] Pulmonary problems The therapeutic agents described herein can be used to treat various pulmonary disorders. The subject can suffer from any pulmonary disease that can benefit from the treatment, such as ischemia, perfusion injury, hypoplastic lung, congenital diaphragmatic hernia (CDH), Poland syndrome, chest wall disease (e.g., pectus excavatum), pneumonectomy, bronchopulmonary dysplasia, lung injury, and inhalation injury, asthma, cystic fibrosis, etc. For example, the subject can have hypoplastic lung. In some embodiments, an effective amount of a composition comprising isolated mitochondria can be administered to the subject, for example, via the airway.
[0115] In some embodiments, the methods described herein can be used to treat acute respiratory distress syndrome (ARDS), acute lung injury (ALI), respiratory failure, respiratory depression, and / or pulmonary inflammation.
[0116] In some embodiments, the methods described herein can be used to treat pulmonary fibrosis, pulmonary infection (e.g., viral, coronavirus, cold, bacterial, or fungal), asthma, chronic obstructive pulmonary disease, pulmonary embolism, lung cancer, pulmonary hypertension, or lymphangioleiomyomatosis. In some embodiments, the methods described herein can be used to treat pneumonia.
[0117] In some embodiments, the subject can be identified as having insufficient, incomplete, or slow lung development. Alternatively or additionally, the subject can have some damage to the lungs. For example, the subject can be a regular smoker or a worker who is frequently exposed to smoke inhalation.
[0118] Treatment of ischemia-related injury The methods described herein can be used to treat ischemic lungs. For example, an effective amount of isolated mitochondria can be administered via the airway. The mitochondria can be internalized by cells within the lung.
[0119] Reperfusion injury is tissue damage caused by blood supply when blood returns to tissue after a period of ischemia or oxygen deprivation. The lack of oxygen and nutrients during ischemia leads to inflammation and oxidative damage when blood flow is restored. Inflammatory response further leads to reperfusion injury in the tissue. Therefore, in some cases, treatment also includes administering an immunosuppressant to the patient. The immunosuppressant can be administered, for example, separately, but can also be administered as a co-treatment with the mitochondrial drug. Alternatively, or in addition, the immunosuppressant can be linked to mitochondria to form a complex mitochondrial drug that can be used for treatment. A particularly useful immunosuppressant is a bisphosphonate.
[0120] In some embodiments, the subject suffers from acute lung injury (ALI). Acute lung injury is often associated with acute respiratory failure and refractory hypoxemia. In some embodiments, the subject has bilateral pulmonary infiltrates consistent with pulmonary edema in the absence of left atrial hypertension. ALI complicates a wide variety of medical and surgical conditions and reflects the pulmonary response to lung injury or precipitating factors. The most common reason for ALI is ischemia / reperfusion injury (IRI). IRI can occur with extracorporeal gas exchange, cardiopulmonary bypass, and pulmonary ventilation and has been shown to have a profound effect on lung function and cell viability, as well as to contribute significantly to increased morbidity and mortality in both pediatric and adult patients. The incidence of ALI in adult patients undergoing cardiac surgery is estimated to range from 53.8% to 73.5%. In pediatric patients, ALI is present in 8-10% of patients requiring mechanical ventilation. The predicted mortality rate of ALI in both pediatric and adult patients is 20-75%. Currently, there is no viable methodology for treating ALI that develops following IRI with the goal of increasing lung survival and function.
[0121] The methods described herein can be used to treat ALI. For example, an effective amount of an aerosolized composition comprising a mitochondrial or complex mitochondrial drug can be administered to the airways of a subject. For example, about or at least 1×10 7 Mitochondria can be administered to the lungs. The injected mitochondria can be internalized by endothelial cells and provide enhanced oxygen consumption, reduce lung resistance and elastance, increase compliance, and / or reduce ischemic area.
[0122] Vasodilation and blood flow The methods described herein can significantly increase blood flow without changing mean blood pressure or heart rate. The ability to increase blood flow without increasing heart rate can be clinically used in angina-type injuries and ischemia / reperfusion-related injuries, as well as in areas of tissue damage where increased blood flow and oxygen delivery may be required. Thus, the methods described herein can be used in arterial intervention to remove blood clots or blockages in blood vessels.
[0123] The methods described herein can also be used to increase blood flow and / or oxygen delivery in various organs or tissues (e.g., heart or lungs) and induce vasodilation in the organs. In some instances, the isolated mitochondria or complex mitochondrial drugs can be used to reduce vascular resistance in the organs (e.g., heart or lungs). The isolated mitochondria or complex mitochondrial drugs can be used to increase blood flow. The isolated mitochondria and / or complex mitochondrial drugs can be added to imaging agents and used to identify and remove blockages in the organs.
[0124] It is noted that the effect of the composition depends on the time from isolation to use. The vasodilatory effect decreases with increasing time from isolation. Without intending to be bound by any theory, it is hypothesized that freshly isolated mitochondria have certain chemicals that can increase blood flow. Therefore, in some methods, the mitochondria are freshly isolated and viable. For example, the mitochondria or complex mitochondrial drug is administered to the subject within about 5 minutes, about 10 minutes, about 20 minutes, about 30 minutes, about 40 minutes, about 50 minutes, about 60 minutes, about 70 minutes, about 80 minutes, about 90 minutes, about 100 minutes, about 110 minutes, about 120 minutes from the time the mitochondria isolation process is started or the mitochondria are isolated. In some cases, the mitochondrial or complex mitochondrial drug is administered to a subject within about 20 minutes to about 60 minutes (e.g., about 20 minutes, about 30 minutes, about 40 minutes, about 50 minutes, about 60 minutes) from the time the mitochondrial isolation process begins or after the mitochondria are isolated.
[0125] In some cases, it is not desirable to increase blood flow (e.g., treating ischemia / reperfusion in the lung, treating cancer). In these cases, the mitochondria or complex mitochondrial drug can be stored for a short time (e.g., about 30 to about 60 minutes) before use. This method can be used to increase tissue viability (e.g., treating ischemia / reperfusion injury) without causing an increase in blood flow. In these cases, the mitochondria or complex mitochondrial drug is administered to a subject at least about 60 minutes (e.g., about 65 minutes, about 70 minutes, about 80 minutes, about 90 minutes, about 100 minutes, about 110 minutes, about 120 minutes) from the time the mitochondria isolation process begins or from the time the mitochondria are isolated.
[0126] Imaging Imaging agents can often be attached to mitochondria by co-incubation of the mitochondria with the imaging agent. Such imaging agents include MitoTracker and pHrodo fluorophores from Thermo Fisher Scientific Inc. 18 F-Rhodamine 6G, and iron oxide nanoparticles, but are not limited to these.
[0127] The complex mitochondrial drug containing the imaging agent can be administered to the subject through the airway.The tissue containing the labeled mitochondria can be examined using imaging techniques such as positron emission tomography (PET), micro-computed tomography (μCT), and magnetic resonance imaging (MRI), bright field microscopy, and 3D super-resolution microscopy.Those skilled in the art will recognize that other imaging techniques or imaging modalities can be used.Such imaging techniques or imaging modalities include, but are not limited to, X-ray, scintigraphy, fluorescence, and ultrasound.
[0128] Positron emission tomography is an imaging technique that produces three-dimensional images inside the body and can be used in the methods described herein. The system detects pairs of gamma rays that are indirectly emitted by a positron-emitting radioisotope (tracer). A three-dimensional image of the tracer concentration in the body is then constructed by computer analysis. Useful reporter groups include: 11 C. 13 N, 15 O. 18 F, 64 Cu, 68 Ga, 81 mKr, 82 Rb, 86 Y, 89 Zr, 111 In, 123 I, 124 I, 133 Xe, 201 T.I., 125 I, 35 S, 14 C. 3 In some methods, mitochondria are fused with radioisotopes, e.g. 18 by F or molecules incorporating radioisotopes, e.g. 18 F-Rhodamine 6G, 18 They can be labeled by F-labeled rhodamine B. After the mitochondria are internalized by the target cells, PET imaging techniques or similar techniques can be employed to observe the target cells.
[0129] Magnetic resonance imaging is a medical imaging technique for imaging the body's anatomical structures and physiological processes and can be used in the methods described herein. In some examples, magnetic resonance imaging can be used in combination with several other imaging techniques, such as PET. Images acquired from either device can be taken consecutively in the same slice and combined into a single superimposed (co-registered) image. PET / MRI scans can be used to diagnose health conditions in humans and animals, for example, for research, medical, and agricultural purposes.
[0130] Micro-computed tomography can be used to recreate a virtual model without destroying the original object, and uses X-rays to create cross-sections of physical objects that can be used in the methods described herein. In some examples, micro-computed tomography can be used in combination with some other imaging techniques, such as PET. Images acquired from either device can be taken consecutively in the same slice and combined into a single superimposed (co-registered) image. Thus, functional imaging obtained by PET, which shows the spatial distribution of metabolic or biochemical activity in the body, can be more accurately aligned or correlated with anatomical imaging obtained by CT scanning. Two-dimensional and three-dimensional image reconstructions can be rendered as a function of common software and control systems.
[0131] 3D structured illumination microscopy, 3D SIM, or 3D super-resolution microscopy allows for the complete 3D visualization of the inner structure of cells and can be used in the methods described herein. Structured illumination microscopy is an imaging method that can double the spatial resolution of conventional wide-field fluorescence microscopy by using spatially structured illumination light. Structured illumination microscopy enhances spatial resolution by collecting information from frequency space outside the observable region.
[0132] The described methods, i.e., methods involving administering mitochondria and / or complex mitochondrial drugs, are useful for diagnosing a variety of diseases, such as cancer (e.g., lung cancer, brain cancer, pancreatic cancer, melanoma, prostate cancer, colon cancer), cardiovascular disease (e.g., myocardial infarction, atherosclerosis), autoimmune diseases (e.g., multiple sclerosis, diabetes, irritable bowel syndrome, celiac disease, Crohn's disease), and inflammatory diseases.
[0133] Methods for using agents for imaging purposes are well known in the art, see, for example, Bartholoma et al, Biological characterization of F18-labeled Rhodamine B, a potential positron emission tomography perfusion tracer, Nucl Med Biol 40, 1043-1048, PMC3820364 (2013); 18 F-labeled rhodamines as potential myocardial perfusion agents: comparison of pharmacokinetic properties of several rhodamines, Nucl Med Biol 42, 796-803, PMC4567415 (2015), and Pacak et al, Superparamagnetic iron oxide nanoparticles function as a long-term, multi-modal imaging label for non-invasive tracking of implanted progenitor cells, PLoS ONE 9, e108695, PMC4177390 (2014). Each of the foregoing can be useful in the methods described herein and are incorporated by reference in their entirety.
[0134] Drug Delivery The present specification provides, for example, a method for delivering a drug to a patient's cells and / or tissues. Mitochondria are taken up by tissue cells via actin-dependent internalization process, thereby providing a method for delivering a drug directly into cells. In some examples, the complex mitochondrial drug enters lung tissue or blood vessels via airways.
[0135] The antibody or antigen-binding fragment can be linked or attached to the mitochondria. One skilled in the art will recognize that the antibody or antigen-binding fragment can be linked to the mitochondria or complex mitochondrial drug to target the mitochondria or complex mitochondrial drug to a specific site, for example, a cell and / or tissue. In some examples, the antibody or antigen-binding fragment is designed to target a specific cell type, for example, intrapulmonary smooth muscle cells, immune cells, macrophages, etc.
[0136] In some embodiments, the present disclosure provides a method for delivering a nucleic acid (e.g., DNA, RNA, mRNA), a vector, a peptide, or a protein to a target site (e.g., lung tissue). Isolated mitochondria can be used as a carrier to deliver a nucleic acid or peptide into a cell. In some examples, a complex mitochondrial drug comprising a nucleic acid polymer can be administered to replace a mutated gene in a subject causing a disease, to inactivate or "knock out" a mutated gene, or to introduce a new gene into a subject. Exemplary nucleic acid polymers include, but are not limited to, double-stranded DNA, single-stranded DNA, double-stranded RNA, single-stranded RNA, or triple-helical nucleic acid molecules. In certain examples, the nucleic acid polymer is DNA, interfering RNA (siRNA), and microRNA.
[0137] Minimizing Cardiac Toxicity Chemotherapy is a common treatment for various cancers, but it also causes some serious complications. Chemotherapy-induced cardiotoxicity is one complication that limits the clinical use of chemotherapy drugs. Certain chemotherapy drugs, such as anthracyclines, are very effective against acute lymphoblastic leukemia and acute myeloblastic leukemia, but are particularly harmful to the heart due to their effect on mitochondria. Damage to mitochondria also leads to chemotherapy-induced cardiotoxicity. Angsutararux et al,Chemotherapy-Induced Cardiotoxicity:Overview of the Roles of Oxidative Stress.Oxid Med Cell Longev.2015;2015:795602.doi:10.1155 / 2015 / 795602(2015), Guo et al.,Cardiovascular toxicities from systemic breast cancer therapy,Front Oncol.4:346.doi:10.3389 / fonc.2014.00346.eCollection(2014).
[0138] The present disclosure provides a method for minimizing chemotherapy-induced cardiotoxicity. The method includes administering an effective amount of isolated mitochondrial and / or complex mitochondrial drug to a patient via the airway. If the patient needs to be treated with chemotherapy (e.g., because prescribed by a physician or veterinarian), the patient can be treated with mitochondrial and / or complex mitochondrial drug before, during, and / or after administration of the chemotherapy. For example, the patient can be treated with mitochondrial and / or complex mitochondrial drug starting immediately after administration as a sole treatment or continued for about 1, 2, 5, 8, 10, 20, 30, 50, or 60 days, 1 year, indefinitely, or until a physician determines that administration of mitochondrial and / or complex mitochondrial drug is no longer necessary, intermittently, or continuously.
[0139] Organ / Tissue Transplantation The disclosure also features a method of transplanting an organ, tissue, cell mass, and / or isolated cell. The method can include exposing the organ, tissue, cell mass, and / or isolated cell to mitochondria or a complex mitochondrial drug prior to transplantation. Such exposure can occur in situ and / or ex vivo. The organ, tissue, and / or isolated cell can be exposed to a composition comprising mitochondria or a complex mitochondrial drug (e.g., an aerosolized composition).
[0140] Exposure of an organ or tissue to a composition comprising mitochondria or a complex mitochondrial drug can be performed ex vivo and / or in situ by any method known in the art. For example, the exposure can be performed ex vivo in any chamber or space having a volume sufficient to completely or partially immerse the organ or tissue in the composition. As another example, an organ can be exposed to a composition comprising mitochondria or a complex mitochondrial drug by placing the organ in any suitable container and allowing the organ to be "flushed" with the composition comprising mitochondria or a complex mitochondrial drug so that the organ is exposed to a continuous flow of the composition.
[0141] An effective amount of a mitochondrial or complex mitochondrial drug is an amount effective to enhance the survival and / or improve the function of an organ or cell in vivo and / or in vitro. In the context of transplantation of an individual cell or cell mass, e.g., transplant donor and / or recipient, an effective amount of a mitochondrial or complex mitochondrial drug is an amount administered to a transplant donor and / or recipient sufficient to enhance the survival of the cell or cell mass, e.g., to reduce the loss of the cell or cell mass, and / or to improve the functional behavior of the transplanted cell or cell mass. In the context of transplantation of organs and tissues, e.g., transplant donor and / or recipient, an effective amount of a mitochondrial or complex mitochondrial drug is an amount administered to a transplant donor and / or recipient sufficient to enhance the survival of the organ, tissue or cell of interest, e.g., to reduce the loss of the cells that constitute the organ or tissue, and / or to improve the functional behavior of the organ.
[0142] In some examples, the administration of the composition via the airway is performed before the organ is retrieved from the donor. In some examples, the administration of the composition via the airway is performed after the organ is transplanted into the recipient. In some examples, the administration of the composition (e.g., the aerosolized composition) is performed before the harvesting of the organ, after the organ is collected, and then after re-implantation into the recipient. In some examples, the administration of the composition is performed during transplant surgery (e.g., lung transplant, heart transplant).
[0143] Cancer Treatment The methods described herein also provide for the treatment of cancer (e.g., lung cancer). After the composition as described herein is administered to a subject via the airway, the mitochondrial or complex mitochondrial drug can be taken up by tumor cells. In some embodiments, a cytostatic or cytotoxic drug can be delivered to the tumor to kill cancer cells. In some embodiments, the therapeutic agent is a chemotherapeutic drug, such as an anthracycline.
[0144] Cancers that can be treated using the methods and compositions of the disclosure include, for example, oral / pharyngeal cancer, esophageal cancer, laryngeal cancer, lung cancer, or any cancer in the respiratory tract.
[0145] Furthermore, in some embodiments, the antibody or antigen-binding fragment can be linked or attached to the mitochondria. One of skill in the art will recognize that linking the antibody or antigen-binding fragment to the mitochondria or complex mitochondrial drug can allow the mitochondria or complex mitochondrial drug to target a specific site, e.g., a cell and / or tissue. In some examples, the antibody or antigen-binding fragment is designed to target a specific cell type, e.g., a cancer cell.
[0146] dosage An "effective amount" is an amount sufficient to produce a beneficial or desired result. For example, a therapeutic amount is an amount that achieves a desired therapeutic effect. This amount may be the same as or different from a prophylactically effective amount, which is the amount necessary to prevent the onset of a disease or disease symptoms. An effective amount can be administered in one or more administrations, applications or dosages. The therapeutically effective amount (i.e., effective dosage) of a therapeutic agent will depend on the therapeutic agent selected. The composition can be administered from once or more times daily to once or more times weekly, including once every other day. One of skill in the art will recognize that certain factors, including but not limited to the severity of the disease or disorder, previous treatments, the general health and / or age of the subject, and other diseases present, may affect the dosage and timing required to effectively treat a subject. Moreover, treatment of a subject with a therapeutically effective amount of a therapeutic agent described herein can include a single treatment or a series of treatments.
[0147] The dosage, toxicity and therapeutic efficacy of therapeutic agents can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, for example, to determine the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population). The dose ratio between the toxic effect and the therapeutic effect is the therapeutic index, which can be expressed as the LD50 / ED50 ratio. Agents that exhibit a high therapeutic index are preferred. Agents that exhibit toxic side effects can be used, but care should be taken to design a delivery system that targets such agents to the site of affected tissues, to minimize potential damage to uninfected cells, thereby reducing side effects. How to estimate the safety range for human patients is described, for example, in Food and Drug Administration.''Guidance for industry: estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers.''Center for Drug Evaluation and Research (CDER) (2005), which is incorporated herein by reference in its entirety.
[0148] Data obtained from cell culture assays and animal studies can be used to formulate a range of dosages for use in humans. The dosage of such agents is preferably within a range of circulating concentrations that include the ED50 with little or no toxicity. The dosage may vary within this range depending on the dosage form employed and the route of administration utilized. For any agent used in the methods of the invention, the therapeutically effective dose can be estimated initially from cell culture assays. Such information can be used to more accurately determine useful doses in humans. Levels in plasma can be measured, for example, by high performance liquid chromatography.
[0149] Those skilled in the art will recognize that the amount of mitochondrial and / or complex mitochondrial drug, e.g., a composition containing mitochondrial and / or complex mitochondrial drug, to be administered to a patient will vary depending, for example, on the type of disorder being treated, the route of administration, the duration of treatment, the size of the area being treated, and / or the location of the treatment site in the patient, among others. Those skilled in the art will be able to determine the dosage to be administered depending on these and other variables. For example, a total of about 1×10 10 ~1×10 14 mitochondria can be administered to a subject (e.g., to treat localized ischemia in the lung). In the case of small central lesions, 1×10 3 ~1×10 6 10 mitochondria can be administered to a patient. Thus, an effective amount of a mitochondria or complex mitochondrial drug (or a composition containing same) is the total amount of mitochondria or complex mitochondrial drug sufficient to produce the desired therapeutic effect. An effective amount is, for example, at least or about 1×10 2 1 x 10 mitochondria or a combination of mitochondrial drugs, e.g., 1 x 10 3 ~Approx. 1×10 14 pieces, about 1×10 4 ~Approx. 1×10 13 pieces, about 1×10 5 ~Approx. 1×10 12 pieces, about 1×10 6 ~Approx. 1×10 11 pieces, about 1×10 7 ~Approx. 1×10 10 pieces, about 1×10 3 ~Approx. 1×10 7 pieces, about 1×10 4 ~Approx. 1×10 6 pieces, about 1×10 7 ~Approx. 1×10 14 pcs, or about 1 x 10 8 ~Approx. 1×10 13 pieces, about 1×10 9 ~Approx. 1×10 12 pieces, about 1×10 5 ~Approx. 1×10 8 1 x 10 or at least or about 1 x 10 3 pieces, 1×10 4 pieces, 1×10 5pieces, 1×10 6 pieces, 1×10 7 pieces, 1×10 8 pieces, 1×10 9 pieces, 1×10 10 pieces, 1×10 11 pieces, 1×10 12 pieces, 1×10 13 1 x 10 or at least or about 1 x 10 14 or, for example, 1 x 10 14 As used herein, the term "total amount" in the context of administration to a patient can refer to the total amount of mitochondria or complex mitochondrial drugs in a single dose or multiple doses, depending on the dosing regimen being implemented.
[0150] Pharmaceutical Compositions The present disclosure provides compositions comprising isolated mitochondria, compositions comprising complex mitochondrial drugs, compositions comprising both isolated mitochondria and complex mitochondrial drugs, and methods of using such compositions.
[0151] The pharmaceutical compositions described herein can include a mitochondrial and / or complex mitochondrial drug and a pharma- ceutical acceptable carrier. As used herein, the term "pharma-ceutical acceptable carrier" includes saline, solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, etc., that are compatible with pharmaceutical administration. In some embodiments, the pharma-ceutical acceptable carrier is phosphate buffered saline, saline, Krebs buffer, Tyrode's solution, contrast agent, or omnipaque, or a mixture thereof. In some embodiments, the pharma- ceutically acceptable carrier is sterile mitochondrial buffer (300 mM sucrose, 10 mM K+-HEPES (potassium buffered (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, pH 7.2), 1 mM K+-EGTA, (potassium buffered ethylene glycol tetraacetic acid, pH 8.0)). In some embodiments, the pharma-ceutically acceptable carrier is respiratory buffer (250 mM sucrose, 2 mM KH2PO4, 10 mM MgCl2, 20 mM K-HEPES buffer (pH 7.2), and 0.5 mM K-EGTA (pH 8.0)).
[0152] A pharmaceutical composition is typically formulated to be compatible with its intended route of administration.
[0153] The pharmaceutical composition can be formulated for various clinical applications, such as imaging, wound treatment, injury treatment, organ preservation, improving mitochondrial function in organs or tissues, and skin care. In some cases, the pharma- ceutical acceptable carrier is a contrast agent for imaging purposes. In some embodiments, the pharmaceutical composition can include antiseptics, antibacterials (e.g., antibiotics), antifungals, disinfectants, analgesics, anesthetics, steroids, dietary supplements, ethereal oils, and the like. Anaesthetics are drugs that can prevent pain during surgery or procedures. Exemplary analgesics include, but are not limited to, paracetamol, nonsteroidal anti-inflammatory drugs, salicylates, ibuprofen, and lidocaine. Exemplary antibacterials include, but are not limited to, dichlorobenzyl alcohol, amylmetacresol, and antibiotics. Exemplary antibiotics include penicillin carbapenems, cephalosporins, aminoglycosides, bacitracin, gramicidin, mupirocin, chloramphenicol, thiamphenicol, lincomycin, clindamycin, macrolides, novobiocin, polymyxins, rifamycins, spectinomycin, tetracyclines, vancomycin, teicoplanin, streptogramins, folate antagonists, sulfonamides, trimethoprim, pyrimethamine, nitrofurans, methenamine mandelic acid, methenamine hippuric acid, nitroimidazoles, quinolones, fluoroquinolones, isoniazid, ethambutol, pyrazinamide, para-aminosalicylic acid, cycloserine, capreomycin, ethionamide, prothionamide, thiacetazone, and viomycin. Antiseptics are antimicrobial substances that can be applied to living tissue / skin to reduce the chance of infection, sepsis, or putrefaction. Exemplary antiseptics include, but are not limited to, chlorhexidine and its salts, benzalkonium and its salts, triclosan and cetylpyridium chloride. Exemplary antifungal agents include, but are not limited to, tolnaftate, miconazole, fluconazole, clotrimazole, econazole, ketoconazole, itraconazole, terbinafine, amphotericin, nystatin, and natamycin.Exemplary steroids include, but are not limited to, prednisone acetate, prednisone valerate, prednisolone, alclomethasone dipropionate, fluocinolone acetonide, dexamethasone, methylprednisolone, desonide, pivalate, clocortolone pivolate, triamcinolone acetonide, predicarbate, fluticasone propionate, flurandrenolide, mometasone furoate, desoximetasone, betamethasone, betamethasone dipropionate, betamethasone valerate, betamethasone propionate, betamethasone benzoate, diflorasone acetate, fluocinonide, halcinonide, amcinonide, halobetasol propionate, and clobetasol propionate. Exemplary dietary supplements include, but are not limited to, vitamins, minerals, herbal products, and amino acids. Vitamins include, but are not limited to, vitamin A, vitamin B group, vitamin C, vitamin D group, vitamin E, and vitamin K. Ethereal oils include, but are not limited to, those derived from mint, sage, fir, lavender, basil, lemon, juniper, rosemary, eucalyptus, marigold, chamomile, orange, and the like. Many of these agents are described, for example, in International Publication No. WO2008152626, which is incorporated by reference in its entirety.
[0154] Compositions containing mitochondria and / or complex mitochondrial drugs can be formulated in any form, such as liquid, semi-solid, or solid. Exemplary compositions include liquids, creams, ointments, salves, oils, emulsions, liposomal formulations, among others.
[0155] The isolated mitochondria or complex mitochondrial drugs can be included in a composition designed for use in organ, tissue, or cell transplantation. The composition can include the isolated mitochondria and / or complex mitochondrial drugs and a liquid suitable for administration to a patient and / or organ in situ or ex vivo, for example, for maintaining the organ, tissue, or cell ex vivo. Generally, the liquid is an aqueous solution. Examples of solutions include phosphate buffered saline (PBS), Ceisior™ solution, Perfadex™ solution, Collins solution, citric acid solution, tissue culture medium (e.g., Dulvecco's modified Eagle's medium (DMEM)), histidine-tryptophan-ketoglutarate (HTK) solution, and University of Wisconsin (UW) solution (Oxford Textbook of Surgery, Morris and Malt, Eds., Oxford University Press, 1994).
[0156] The University of Wisconsin refrigerated preservation solution is considered the standard solution for organ transplantation. It contains the following: 100 mM potassium lactobionate, 25 mM KH2PO4, 5 mM MgSO4, 30 mM raffinose, 5 mM adenosine, 3 mM glutathione, 1 mM allopurinol, and 50 g / L hydroxyethyl starch. Isolated mitochondria or complex mitochondrial drugs can be added to these fluids for the preservation of organs, tissues, and cells.
[0157] When administered via certain routes, such as the airways (e.g., nose, tracheotomy, or endotracheal tube (ETT)), surfactants can enable the composition to reach the distal airways. Thus, in some embodiments, the compositions described herein (e.g., liquid solutions, aqueous solutions (if water soluble), aerosol formulations, dispersions, sterile powders, etc.) can include one or more surfactants.
[0158] The surfactant can be selected from the group consisting of nonionic, cationic, anionic, and zwitterionic surfactants. A mixture of surfactants can also be used. Exemplary types of surfactants include alcohol ether sulfates, alcohol sulfates, alkanolamides, alkylsulfonates, amine oxides, amphoteric surfactants, anionic surfactants, betaine derivatives, cationic surfactants, disulfonates, dodecylbenzenes, sulfonic acids, ethoxylated alcohols, ethoxylated alkylphenols, ethoxylated fatty acids, glycerol ester hydrotropes, lauryl sulfates, mono- and diglycerides, nonionic surfactants, phosphate esters, quaternary surfactants, and sorbitan derivatives.
[0159] Several other suitable pharmaceutical carriers can also be used, as they are suitable for delivery through the airways. These carriers include, for example, liposomes, nanoparticles and microparticles, cyclodextrins, microemulsions, micelles, suspensions, or solutions. In some embodiments, these carriers are made of lipids (e.g., liposomes, niosomes, microemulsions, lipid micelles, solid lipid nanoparticles) or composed of polymers (e.g., polymeric micelles, dendrimers, polymeric nanoparticles, nanogels, nanocapsules). These carriers can deliver therapeutic agents to the lungs in a controlled manner. Nanocarriers can also be used. Localized therapy of target organs generally requires a smaller total dose to achieve clinically effective results. To achieve this goal, nanocarriers can be engineered to be slowly degrading, responsive to stimuli, and site-specific.
[0160] The pharmaceutical compositions described herein can be included in a container, pack, or dispenser accompanied by instructions for administration. The pharmaceutical compositions described herein can also be prepared in a form suitable for conversion into an aerosolized form (e.g., by a suitable nebulizer). EXAMPLES
[0161] The invention is further described in the following examples, which do not limit the scope of the invention described in the claims.
[0162] Example 1: Isolation of mitochondria from autologous skeletal muscle from a subject Mitochondria were isolated from autologous skeletal muscle tissue. The source of tissue depended on the surgical site and its vicinity. Highly effective mitochondrial transplantation typically requires freshly isolated, viable, and functional mitochondria. Non-viable mitochondria (e.g., previously frozen mitochondria), mitochondrial fractions (proteins, complexes I-V), mitochondrial DNA and RNA, and exogenous ATP or ADP usually do not have sufficient functionality.
[0163] method To allow for the isolation of viable, respiration-competent mitochondria, we developed a rapid method for mitochondrial isolation and purification that can be performed in 20-30 min (Figure 1). The main advantages of this method are that (1) it requires only small amounts of tissue (<0.01 g tissue), which can be isolated using a sixth biopsy punch, (2) it uses a standardized tissue dissociation process that allows for uniform and consistent homogenization of tissue that is not easily achieved using manual homogenization methods, and (3) the use of differential filtration, rather than centrifugation, eliminates time-consuming repeated centrifugation steps and reduces preparation time. Briefly, two small pieces of skeletal muscle tissue (<0.1 grams) were obtained using a sixth biopsy punch. The tissue was homogenized in a 5 mL volume of isolation buffer (300 mmol / L sucrose, 10 mmol / L HEPES-KOH, 1 mmol / L EGTA-KOH, pH 7.4) and then incubated with subtilisin A enzyme on ice for 10 min. The digested tissue was then filtered through a series of filters pre-wetted with isolation buffer, and the mitochondria were subsequently sedimented by centrifugation at 9×G for 5 min at 4°C.
[0164] result Figures 2A-G show representative results for the isolation of mitochondria from skeletal muscle. Figure 2A shows skeletal muscle tissue obtained using a biopsy punch. Figure 2B shows representative microscopy images of isolated mitochondria under phase contrast illumination (bright field, BF) (left panel) and under fluorescence labeled with MitoTracker Red CMXRos (middle panel). Merged images are shown in the right panel. Mitochondria obtained by this method have a viability of more than 99%. Figure 2C shows the results for mitochondrial yield per gram of tissue wet weight. Figure 2D shows a representative transmission electron microscopy image of isolated mitochondria. The isolated mitochondria were electron dense, with less than 0.01% of the mitochondria being destroyed or damaged ( * ). Figure 2E shows representative activity results for mitochondrial complexes I-V. Figure 2F shows representative results for state 3 (active) oxygen consumption (ADP-stimulated respiration). Figure 2G shows representative results for respiratory control index (RCI, state 3 / state 4) for malate-induced (complex I) and succinate-induced (complex II) oxygen consumption in energized autologous pectoralis major mitochondria. The data showed that isolated mitochondria maintained membrane potential and viability. In addition, the data showed that oxygen consumption and respiratory control index for malate-induced complex I and succinate-induced complex II were equivalent to those of mitochondria isolated by several other methods.
[0165] Example 2: Isolated mitochondria remained present and viable for at least 28 days after injection into the myocardium Once isolated by methods such as those described in Example 1, the mitochondria were immediately used for mitochondrial transplantation.
[0166] Mitochondrial Dosage Experiments were performed to determine the optimal dose of autologous mitochondria. These experiments consisted of 2 × 10 mitochondria per gram of wet tissue weight. 5 It has been demonstrated that one mitochondria provides optimal efficacy.
[0167] Delivery of isolated mitochondria Isolated mitochondria were delivered either by direct injection into the ischemic area of the lung via intravascular infusion or by a nebulizer. (a) Direct injection of mitochondria provides localized distribution of mitochondria. Mitochondria were injected into the pulmonary artery or right atrium using a tuberculin syringe with a 28-gauge needle. (b) Intravascular delivery of mitochondria simplifies mitochondrial delivery to tissues and allows for widespread distribution of autologous mitochondria within tissues. (c) Nebulized delivery of mitochondria. To increase applicability and allow for early non-surgical and post-operative intervention, autologous mitochondria were delivered to the lungs by nebulizer.
[0168] Vascular delivery provides localized delivery. Preliminary studies were performed to demonstrate the safety and efficacy of delivery of autologous mitochondria by intravascular delivery via the right atrium and pulmonary artery. Preliminary results demonstrated that transplantation of autologous mitochondria delivered via either of these routes provides tissue-specific delivery and uptake of mitochondria, is safe and effective, and significantly enhances lung function after 2 hours of ischemia and 24 hours of recovery.
[0169] result Fluorescence microscopy and MRI demonstrated that transplanted mitochondria were present and viable for at least 28 days after injection into the myocardium. The majority of mitochondria were initially found within the intercellular spaces. Within 30 min after delivery, transplanted mitochondria were internalized into the cells by endocytosis and were found within cardiomyocytes residing near the sarcolemma between the Z-lines of the sarcomeres, as well as in clusters around endogenous damaged mitochondria and near the nucleus. Enumeration of injected mitochondria showed that 43.52% ± 4.46 (mean ± SEM) of injected mitochondria were found attached to or within cardiomyocytes. Three-dimensional super-resolution microscopy and transmission electron microscopy were used to determine the intracellular fate of endocytosed exogenous mitochondria in human iPS-derived cardiomyocytes and primary cardiac fibroblasts. The results showed that isolated mitochondria were incorporated into cardiac cells within minutes and then transported into the cells by endocytosis, where they fused with the endogenous mitochondrial network.
[0170] Figures 3A-D show representative results of the uptake and endocytic transport of extracellular mitochondria in cardiomyocytes. Figure 3A shows representative images of iPS-CMs exposed to gold-labeled HCF mitochondria for 2.5, 5, and 10 min and imaged by TEM. Labeled mitochondria had electron-dense deposits and were evident outside the cell, adjacent to the apical cell surface, undergoing endocytosis, and inside the cell (indicated by arrows, from left to right) at all three time points tested. Images are representative of four experiments at 5 min, scale bar 0.5 μm. Figure 3B shows representative images from four-color 3D SR-SIM of exogenous mitochondria colocalization with early endosomes at 4 h. Nuclei were stained with DAPI, and both endogenous and exogenous mitochondria were detected with MTC02 antibody. Merged images (left) and individual colors (right) are shown, scale bar 10 μm. Figure 3C shows a representative overlay microscopy image of HCF mitochondria and late endosomes at 1 hour, scale bar 10 μm. Figure 3D shows a representative overlay microscopy image of mitochondria and lysosomes at 4 hours, scale bar 10 μm. In Figures 3C and 3D, arrows indicate examples of exogenous mitochondria associated with each compartment that also reacted with anti-mitochondrial MTC02 antibody. Nuclei were stained with DAPI and images represent 12 separate volumes analyzed at each time point (0.5, 1, 2, and 4 hours), scale bar 0.5 μm.
[0171] The transplanted mitochondria were not arrhythmogenic, as evidenced by continuous 12-lead electrocardiogram analysis and optical mapping. There was no change in continuous ECG, QRS duration, or corrected QT interval associated with mitochondrial transplantation, as there was no ventricular tachycardia, bradycardia, fibrillation, or conduction system defects or repolarization heterogeneity. There was no change in ventricular wall motion disorder, left ventricular hypertrophy, valvular dysfunction, fibrosis, or pericardial effusion, either at the time of autologous mitochondrial injection or at any time point up to 4 weeks after transplantation. In addition, the transplanted mitochondria did not produce an immune or inflammatory response. Autoimmune responses were undetectable, as measured by antimitochondrial antibodies using indirect immunofluorescence.
[0172] Transplanted mitochondria can act both extracellularly and intracellularly. Once transplanted, mitochondria maintain viability and function for at least 28 days, the limit of the time of testing performed to date. Transplanted mitochondria can also immediately increase myocardial ATP levels and ATP synthesis, and can rapidly alter the myocardial proteome. Proteomic analysis 10 min after injection showed that protein pathways for mitochondria and the production of precursor metabolites of energy and cellular respiration were significantly higher in treated hearts compared to control hearts (P<0.05, enrichment score>2.0), when improvement in ventricular function was first observed by epicardial echocardiography. Between 10 and 60 min after transplantation, transplanted mitochondria were internalized into cardiomyocytes by actin-dependent endocytosis. The number of mitochondria internalized into binucleated cardiomyocytes was 40.9±11 per nucleus after 1 h and 218.7±63.7 per nucleus after 24 h. Once internalized, transplanted mitochondria further increase cellular ATP content (p<0.05) and upregulate cardioprotective cytokines (epidermal growth factor, growth-related oncogene, IL-6 and monocyte chemotactic protein 3). These cytokines are associated with enhanced cardiac function by stimulating cell growth, proliferation and migration, enhancing angiogenesis, providing protection against cardiomyocyte apoptosis, and improving functional cardiac recovery and cardiac remodeling independent of cardiomyocyte regeneration. Ischemia also damages mitochondrial DNA and reduces ATP synthesis, and these changes have been associated with poor recovery after cardiac surgery in humans. This example demonstrated that mitochondrial transplantation at least partially replaced damaged mitochondrial DNA with intact mitochondrial DNA and rescued cardiomyocyte function.
[0173] Example 3: Preliminary studies in animals and humans The efficacy of mitochondrial transplantation was examined in a series of in vitro and in vivo animal heart perfusion models. Results from these studies demonstrated that mitochondrial transplantation rescues cardiomyocyte viability and significantly enhances postischemic myocardial function following ischemia-reperfusion injury.
[0174] Using ischemia / reperfusion protocols in isolated perfused hearts and in situ regional ischemic heart models, autologous mitochondrial transplantation was demonstrated to be safe and effective. The study demonstrated that both direct and vascular delivery of mitochondria significantly improved ischemia / reperfusion injury and enhanced cardiomyocyte viability and postischemic functional recovery of the myocardium. These effects were evident for at least 28 days, the endpoint of the in situ survival experiments.
[0175] Pediatric patients with significant IRI require mechanical support with extracorporeal membrane oxygenation (ECMO). The use of ECMO has been shown to be a life-saving technique, but it can lead to complications with bleeding, systemic inflammatory responses, and infections, and therefore can only be used for a limited period of time. If myocardial recovery is not achieved within the ECMO support period, patients will eventually succumb to ECMO complications, which can cause IRI both while the patient is intubated and after intubation. Studies have shown that patients unable to be weaned from ECMO support within 72 hours is a significant prognostic indicator, with an overall survival rate of less than 30%. A human pilot study was performed to demonstrate that direct injection of autologous mitochondria significantly improved ventricular function in five pediatric patients, allowing weaning from ECMO. None of the patients experienced any adverse effects, and there were no complications of arrhythmias, intramyocardial hematomas, or inflammatory responses. This pilot study was the first clinical application of the novel technique of autologous mitochondrial transplantation to improve cardiac function in patients with IRI.
[0176] Example 4: Administration of exogenous mitochondria in aerosol form to the airways results in localization to (and internalization within) cells lining the airways To assess whether exogenous mitochondria prepared in an aerosol form and administered to the airways would result in localization (and internalization) to cells lining the airways, aerosols containing labeled mitochondria were prepared and administered using a nebulizer system, and biodistribution within lung tissue was assessed.
[0177] method Animal models A mouse model of pulmonary ischemia / reperfusion injury was chosen for the experiments. C57BL / 6J mice are well characterized and are an established model for use in ALI, allowing for comparison of outcomes.
[0178] Biodistribution Visualization of exogenous mitochondrial biodistribution in the lung was performed in rats rather than mice to enhance visualization and distribution analysis. The mouse model does not provide a sufficient area to detect biodistribution. Briefly, Wistar rats (200 g) were anesthetized with an intraperitoneal injection of sodium pentobarbital (100 mg / kg) and maintained with 0.5% isoflurane inhalation. Oral endotracheal intubation using a 20-gauge plastic catheter was performed, and the rats were mechanically ventilated with a tidal volume of 10 mL / kg and a respiratory rate of 130–140 breaths / min. A left thoracotomy was performed at the third intercostal space to expose the pulmonary artery. Biodistribution of exogenous mitochondrial tissue was analyzed using a 3-well plate. 18 This was determined by labeling human cardiac fibroblast mitochondria with F-rhodamine 6-G. The use of human mitochondria in rat, mouse or pig models allows for the distinction between native and transplanted mitochondria based on immunoreactivity to monoclonal anti-human mitochondrial antibodies.
[0179] vascular delivery 18 F-Rhodamine 6-G-labeled human cardiac fibroblast mitochondria were delivered as a 0.3 mL bolus in respiratory buffer (250 mmol / L sucrose, 20 mmol / L K+-HEPES buffer, pH 7.2, 0.5 mmol / L K+-EGTA, pH 8.0) via injection into the left pulmonary artery using a tuberculin syringe with a 40-gauge needle.
[0180] Nebulizer Delivery in 90 μL of respiration buffer 18F-rhodamine 6-G-labeled human cardiac fibroblast mitochondria were delivered to the whole lung for 40 seconds using a Flexivent nebulizer (10 seconds of nebulization followed by 1 minute of periodic mechanical ventilation, repeated four times).
[0181] Measurement of mitochondrial concentration Mitochondria were allowed to circulate for 30 min after delivery to allow for washout, and then rats were euthanized by carbon dioxide overdose. Mitochondrial biodistribution was determined by positron emission tomography (PET) and microcomputed tomography (μCT) using an Albira PET / SPECT / CT Preclilnical Imaging System (Bruker, Billerica, MA).
[0182] Quantifying cellular uptake of delivered mitochondria To confirm the presence of exogenous mitochondria in lung tissue and to identify pulmonary cellular uptake, lung sections were obtained from the left and right lungs, fixed in paraffin, and subjected to immunohistochemical analysis.
[0183] result Figures 4A-C show that IgG4 was delivered to the lungs by vascular injection via the pulmonary artery in a rat model and imaged using positron emission tomography (PET) and microcomputed tomography (μCT) using an Alvira Imaging System (Bruker, Billerica, MA). 18 F Rhodamine 6-G mitochondria (6 × 10 7 These results show that delivery of mitochondria to the lung results in specific distribution of the transplanted mitochondria throughout the lung.
[0184] Figures 5A-B show the results of immunohistochemical detection and cellular uptake of exogenous mitochondria in mouse lung tissue delivered via the pulmonary artery by a nebulizer. Human cardiac fibroblast mitochondria were detected using an anti-human mitochondrial antibody (MTC02 [biotin]-Abcam, Cambridge, UK, Cat. No. ab79479) and Vectastain Elite ABC (Vector Laboratories, Burlingame, CA) and AEC+ substrate chromogen (Dako, Agilent, Santa Clara, CA). The use of human mitochondria in rat, mouse or pig models allows for the distinction between native and transplanted mitochondria based on immunoreactivity to monoclonal anti-human mitochondrial antibodies. In the figures, mitochondria are shown as black dots. Mitochondria were detected in and around pulmonary endothelial cells, pneumocytes, parenchyma, and alveoli.
[0185] Example 5: Exogenous mitochondria prepared as an aerosol form and administered to the airways can improve symptoms of acute pulmonary ischemia (ALI) To evaluate whether exogenous mitochondria prepared in an aerosol form and administered to the airways of mice are sufficient to ameliorate symptoms of acute pulmonary ischemia (ALI) in a mouse ALI model, aerosols containing labeled mitochondria were prepared and administered using a nebulizer system, and assays were performed to evaluate lung function and integrity.
[0186] method Animal models Male C57BL / 6J mice (8-10 weeks old; Jackson Laboratory, Bar Harbor, Maine) were used. All experiments were approved by the Boston Children's Hospital Institutional Animal Care and Use Committee and conformed to the National Institutes of Health Guide for the Care and Use of Animals.
[0187] Mitochondrial isolation Mitochondria were isolated from skeletal muscle obtained from syngeneic C57BL / 6J mice. There was no direct or indirect, acute or chronic alloreactive, allorecognition or damage-associated molecular pattern molecule (DAMP) response to single or continuous injections of syngeneic mitochondria. Briefly, skeletal muscle from C57BL / 6J mice was excised and used immediately to isolate syngeneic mitochondria. Mitochondria were isolated and the number and viability of isolated mitochondria were determined. Isolated mitochondria were suspended in 0.3 mL of respiration buffer and used immediately for mitochondrial transplantation.
[0188] Murine pulmonary ALI model: To induce ischemia / reperfusion injury, surgery was performed and the left hilum was occluded for 2 h. Briefly, C57BL / 6J mice were anesthetized by intraperitoneal injection of sodium pentobarbital (100 mg / kg) and maintained with 0.5% isoflurane inhalation throughout surgery. Oral endotracheal intubation using a 20-gauge plastic catheter was performed and mice were mechanically ventilated with a tidal volume of 10 mL / kg and a respiratory rate of 130–140 breaths / min. A left thoracotomy was performed at the third intercostal space to expose the left hilum.
[0189] Acute pulmonary ischemia: The left hilum was occluded at the end of expiration for 2 hours using a microvascular clamp (Roboz Surgical Instrument Co., Gaithersburg, MD, USA) to reduce tidal volume to 7.5 mL / kg. The surgical incision was covered with gauze soaked in a heparin solution containing (60 UI / 1 ml heparin). At the end of the ischemic period, the clips were removed.
[0190] Experimental Group: The animals were randomized into three experimental groups. (a) Vascular Delivery (V): Immediately following the ischemic period and removal of the clips, animals were randomly selected to receive either 0.3 mL of respiratory buffer (Vehicle-V) or 0.3 mL of respiratory buffer containing mitochondria (Mitochondria-V). Vehicle and mitochondria were delivered as a 0.3 mL bolus via injection into the left pulmonary artery using a tuberculin syringe with a 40-gauge needle. Mitochondrial concentrations were determined by the methods described herein. (b) Nebulization (N): Immediately after the ischemic period and removal of the clips, animals were randomly selected to receive either 90 μL of respiratory buffer (vehicle-N) or 90 μL of respiratory buffer containing mitochondria (mitochondria-N). Vehicle and mitochondria were delivered to the whole lung for 40 s using a Flexivent nebulizer (10 s of nebulization followed by 1 min of periodic mechanical ventilation, repeated 4 times). Mitochondrial concentrations were determined. A 3x concentration was used to account for the 2 / 3 larger volume in the nebulizer test (including the right and left lobes). (c): Sham control mice were subjected to thoracotomy without hilar clamps and mechanically ventilated for 2 h before being returned to their cages. A sham control group is needed to isolate specific effects caused by anesthesia, incision trauma and potential trauma to the animal tissues during surgery.
[0191] To determine the optimal mitochondrial concentration required to enable amelioration of ALI. 2 x 10 per gram of wet tissue weight 5 Autologous mitochondria provide cardioprotection in the heart. To determine the optimal mitochondrial concentration for safety and efficacy in the lungs of ALI, several doses were administered, specifically 2 x 10 mitochondria per gram of wet tissue weight. 5 pieces, 2×10 6 pcs and 2 x 10 7 mitochondria were tested.
[0192] Lung function analysis After 24 h of recovery (reperfusion of the ischemic lung), mice were anesthetized by intraperitoneal injection of sodium pentobarbital (70 mg / kg). Tracheotomy or endotracheal intubation with a plastic 18-gauge catheter was performed and mice were mechanically ventilated. A median laparotomy and sternotomy were performed to expose the lungs and the left hilum was clamped to assess the function of the injured left lung. The tidal volume (TV) was reduced to 5 mL / kg and mice were then connected to a specialized rodent ventilator (FlexiVent, SCREQ, Montreuil, Quebec, Canada) to assess peak inspiratory pressure (PIP), respiratory resistance (Rrs), respiratory compliance (Crs), respiratory elastance (Ers) and tissue damping (G) of the left lung.
[0193] Damage-associated molecular pattern (DAMP) analysis To determine whether there was any DAMP-related damage associated with the injection of syngeneic or allogeneic mitochondria, circulating free mitochondrial DNA was detected. Proprietary primers were used that allow for the estimation of circulating free mtDNA, and this method takes into account nuclear mitochondrial insert sequences that may affect the accurate quantification of mtDNA. Briefly, total DNA (nuclear and mitochondrial) was extracted using the DNeasy Blood & Tissue kit according to the manufacturer's instructions (Qiagen, Valencia, CA). DNA was quantified by Nanodrop2000 (Thermo Scientific, Wilmington, DE) and adjusted to 10 ng / uL. Circulating free mitochondrial DNA (mtDNA) was analyzed by quantitative real-time polymerase chain reaction.
[0194] Mouse mtDNA was amplified using primers (Eurofins Genomics, Louisville, KY) for mouse mtDNA (mMitoF1, (5'→3')CTAGAAACCCCGAAACCAAA (SEQ ID NO: 1), mMitoR1 (5'→3')CCAGCTATCACCAAGCTCGT (SEQ ID NO: 2)) and mouse β2 microglobulin (mB2MF1: (5'→3')ATGGGAAGCCGAACATACTG (SEQ ID NO: 3), mB2MR1: (5'→3')::CAGTCTCAGTGGGGGTGAAT (SEQ ID NO: 4)). Real-time PCR was performed using QuantiFast SYBR Green PCR kit (Qiagen, Valencia, CA). All assays were performed using an Eppendorf Mastercycler ep realplex2 machine (Eppendorf, Hauppauge, NY). Real-time PCR (quantitative PCR) conditions consisted of a 5 min preincubation at 95°C, followed by 40 cycles of denaturation at 95°C for 10 s, annealing at 56°C for 15 s, and extension at 60°C for 15 s. After the quantitative PCR run was completed, a melting curve analysis was performed consisting of melting at 95°C for 5 s, cooling at 65°C for 60 s, followed by heating to 95°C while continuously monitoring fluorescence, and finally cooling at 40°C for 30 s. mtDNA fold changes were normalized to single copy nuclear DNA using the formula 2-ΔCt (ΔCt=CtMtDNA-CtB2M).
[0195] Imaging of stained lung tissue to assess lung integrity Lungs were harvested and divided into three equal parts. The upper part of the lung was used to assess tissue edema by calculating the wet / dry (w / d) weight ratio. Lungs were weighed immediately after collection (wet weight) and placed in a 70°C oven for 72 h, after which they were weighed again (dry weight) and the w / d weight ratio was calculated. The central part of the lung was immediately fixed in 10% formalin. Tissues were paraffin embedded and sectioned at a thickness of 5 μm. Serial sections were used for hematoxylin and eosin (H&E) staining, myeloperoxidase staining and TUNEL assay. The lung bases were used for transmission electron microscopy to analyze structural damage within the lung. H&E stained sections were evaluated as a readout of the severity of lung injury using a scoring system. 25 random (20x) fields per section were analyzed. Lung injury was graded based on infiltration or aggregation of inflammatory cells in the airspaces or vessel walls. Grade 1: Walls only, Grade 2: A few cells in the air space (1-5 cells); Grade 3: Intermediate, and Grade 4: Severe (airspace congestion).
[0196] For interstitial congestion and hyaline membrane formation, the following grades are used: Grade 1: normal lungs; Grade 2: moderate (25% of lung sections); Grade 3: intermediate (25-50% of lung sections); Grade 4: severe (50% of lung sections);
[0197] For bleeding, the following scale is used: Grade 0: None, and Grade 1: Yes.
[0198] result Figure 6 shows representative macroscopic images of mouse lungs after 2 hours of ALI ischemia of the left lung and 24 hours of recovery. Lungs subjected to the ischemic procedure are indicated by red circles. The right lung is indicated as R and the left lung as L. The heart (H) is shown in each image. Vehicle lungs exhibited severe edema and cellular damage (Vehicle-V). In contrast, lungs receiving mitochondrial treatment preserved cellular architecture by macroscopic examination.
[0199] Figures 7A-7B show quantitative measurements of lung integrity in mouse lungs, specifically lung resistance and elastance (n=4). Resistance (Figure 7A) and elastance (Figure 7B) were measured in mouse lungs subjected to 2 hours of left pulmonary ischemia after 24 hours of recovery. Vehicle or mitochondria were delivered intravascularly via the left pulmonary artery (V) or by nebulizer (N). Mitochondrial concentrations were 2 x 10 per gram wet weight of lung tissue. 7 The mitochondria delivered by the nebulizer were 6 × 10 mitochondria per gram of wet lung tissue, taking into account the additional lung volume. 7 The results demonstrate that mitochondrial transplantation delivered intravascularly or by aerosol using a nebulizer significantly preserves lung resistance and elastance compared to vehicle-treated lungs. The results also show that there are no significant differences between sham controls (no ischemia) and ischemic lungs that received mitochondria delivered intravascularly via the left pulmonary artery or by nebulizer. Similar results were obtained for tissue damping and lung compliance.
[0200] FIG. 8A shows that respiration buffer alone (sham) or mitochondria (3×10 7Figure 8 shows quantification of circulating free mtDNA determined by real-time PCR on whole blood samples from BALB / cJ mice administered mitochondrial injections (100 mg / kg / day). Blood samples were obtained 10 days after intraperitoneal injection. mtDNA fold change (mean ± SEM) was normalized to single copy nuclear DNA (β2 microglobulin). Results show no increase in circulating free mtDNA with mitochondrial injection compared to sham (P = 0.96). Figure 8B shows representative photomicrographs of lung tissue stained with hematoxylin and eosin. Figure 8C shows representative photomicrographs of lung tissue stained with Masson's trichrome. Lung histology showed no ultrastructural differences in serial lung sections with mitochondrial injection compared to sham. All sections show normal epithelium from airways and alveoli. Figure 8D shows representative transmission electron micrographs from the right lower lobe. Electron microscopy images show preserved endothelium and basement membrane in all groups. Scale bar is 1 μm. Arrows indicate alveolar space. Histological and electron microscopic analysis of lung tissue showed no evidence of inflammation or cellular injury. There was no evidence of myocardial cell necrosis as determined by TTC staining, and no evidence of increased collagen content in myocardial tissue or pulmonary endothelial or basement membrane injury.
[0201] Example 6: Exogenous mitochondria prepared as an aerosol form and administered to the airways are sufficient to ameliorate symptoms in a porcine ALI model Pig lungs have a comparable volume to human lungs, making them an advantageous model for studying respiratory function. Pig lungs have comparable cellular lineages and composition to human lungs. The general anatomical distribution of the porcine airways reproduces that of humans with some minor exceptions. The cartilage surrounding the porcine airways is more widely distributed than in humans, extending further down the tracheobronchial tree. Pig lungs have only three generations of bronchioles after the last cartilage plate before reaching the lobule, whereas humans have roughly 10 generations. Other minor differences include longer porcine terminal bronchioles and shorter, less well-defined porcine respiratory bronchioles. Also, like humans, pigs have a full set of innate immune effectors in their airways that are necessary to protect mucosal surfaces, elicit inflammatory responses, and orchestrate adaptive immune responses. Thus, replicating experiments in large animal models (e.g., porcine models) using the same tools and protocols used in humans can provide better relevance to clinical use in humans.
[0202] method Animal models Yorkshire pigs (male and female, 40-50 kg) were randomly assigned to each group. The porcine model has many advantages in terms of clinical relevance. The physiological properties of the pig closely resemble those of adult humans, and the model can provide surgical relevance for experimental proof-of-concept prior to transfer to human practice. The porcine lung is an excellent model for the normal human lung and is an established pulmonary ischemia-reperfusion injury model.
[0203] Experimental protocol Pigs are induced with Telazol (4-6 mg / kg, intramuscular) and Xylazine (1.1-2.2 mg / kg, intramuscular), followed by auricular vein catheterization. Animals are intubated with a cuffed endotracheal tube and mechanically ventilated via volume-controlled ventilation with TV 10 ml / kg, FiO2 0.4, PEEP 5 cmH2O, and RR 12-15 breaths / min adjusted to obtain a PaCO2 35-45 mmHg at baseline. General anesthesia is induced with isoflurane (maximum 3%) and maintained using 0.5-4%).
[0204] Blood collection A femoral artery catheter is placed percutaneously to monitor mean arterial pressure (MAP) and for arterial blood sampling throughout the procedure. Alternatively, a carotid artery catheter placed via an incision can be utilized. The femoral or jugular vein can be cannulated with a percutaneously placed catheter for CVP monitoring and venous blood sampling. If it is not possible to cannulate these vessels using ultrasound, an incision is made and a catheter is placed in the vessel under direct visualization. The wound is then sutured with Vicryl or PDS sutures (4-0). Heparin sodium 200UI / kg is given via the auricular vein prior to clamping of the left hilum to reach a target ACT >300 seconds. ACT is checked throughout the procedure and, if necessary, coagulation can be adjusted with additional heparin doses to maintain an ACT >300 seconds. If ventricular fibrillation occurs during the procedure, 1% lidocaine (5mL, intravenous) is given to the subject. Lactated Ringer's solution or saline is infused via the auricular or femoral vein throughout the procedure to support arterial blood pressure. After confirmation of deep anesthesia, a left thoracotomy is performed over the fifth intercostal space to access the left hilum. Alternatively, a median sternotomy can be used if access to the hilum is limited in the open chest approach. The pulmonary artery is cannulated with a PVC umbilical catheter for PAP monitoring. The left atrium is then cannulated via the left atrial appendage using a PVC umbilical catheter to measure LAP for blood sampling. Core temperature is continuously monitored and maintained using a heating pad.
[0205] blood flow monitoring The ascending aorta and main pulmonary artery can be dissected and transonic flow probes are attached to monitor blood flow.
[0206] Assessment of myocardial function Myocardial function can be assessed by placing conductance catheters directly into the RV and LV cavities. The catheters can be inserted through a purse string suture. The purse string suture can prevent bleeding and secure the catheter in place. Alternatively, the RV catheter can be placed through the central venous system via the jugular vein. Recordings can be obtained continuously throughout the experiment.
[0207] Echocardiography Echocardiography can be performed to determine myocardial function. Epicardial 2-dimensional echocardiograms are obtained at baseline, immediately prior to injection of autologous mitochondria or respiratory buffer, and 3 hours after injection.
[0208] Isolation of mitochondria The pectoralis major or rectus abdominis muscles can be located and dissected, and two small pieces of muscle tissue (approximately 0.01 g) can be surgically removed using a biopsy punch and used for mitochondrial isolation under sterile conditions, which can be performed in less than 30 minutes according to current laboratory standards to maintain clinical relevance.
[0209] Acute left pulmonary ischemia The left main bronchus can be stripped over a length of 1 cm to excise any bronchial circulation. The hilum-artery, vein and bronchus are clamped for 90 minutes. Ventilation can be adjusted for one-lung ventilation up to TV 6 ml / kg, PEEP 5 cmH2O, and FiO2 is adjusted based on SO2 levels. One-lung ventilation is maintained for 90 minutes. If the maximum airway pressure Pmax rises to as high as 20-22 cmH2O during the ischemic period, volume-controlled ventilation can be switched to pressure-controlled ventilation with Pmax 20-22 cmH2O to prevent pulmonary barotrauma. Bronchial clamping can be visually confirmed by a deflated left lung with no inspiratory or expiratory movements.
[0210] Experimental Group: (a) Sham control group - the left hilum can be dissected but not clamped (no left lung ischemia is present) and animals can be monitored for 90 min and then for an additional 3 h during reperfusion. After 90 min of left lung ischemia, the hilar clamp can be released and the left lung receives either a single 15 mL injection of sterile respiratory buffer (Vehicle-V) or a single 15 mL injection of sterile respiratory buffer containing mitochondria (Mitochondria-V). (b) Vascular delivery of mitochondria or vehicle injections can be administered as a bolus into the left pulmonary artery using an 18-gauge needle, and the injection site can be sutured with size 4-0 Prolene suture to control bleeding. (c) Nebulized delivery can be performed using a commercially available grade nebulizer (Allied Health Care) attached to the ventilator circuit.
[0211] Reperfusion is allowed to continue for 3 hours, during which time the animals remain under anesthesia.
[0212] Data collection MAP, CVP, PAP, LAP are recorded at baseline, at the beginning of the reperfusion phase, immediately before injection of autologous mitochondria or respiratory buffer, and at 1, 2, and 3 hours during reperfusion. Peak inspiratory pressure, plateau inspiratory pressure, and ABG arterial and mixed venous blood respiratory measurements are performed at baseline, at the beginning of the reperfusion phase, immediately before injection of autologous mitochondria or respiratory buffer, and at 1, 2, and 3 hours during reperfusion.
[0213] Bronchoalveolar lavage Lavage of the left and right lungs can be performed at the end of the reperfusion phase. Lavage can be performed under bronchoscope guidance after introducing a catheter via the oral cavity through the trachea, first of the posterior lobe of the left lung and then of the right lung. 30 ml of saline can then be introduced into the lungs and the fluid can be aspirated after 1 minute. This can be followed by an additional 15 ml of saline being introduced into the lungs and aspirated after 1 minute. The aspirated fluid can be collected for further analysis. The BAL fluid can be immediately centrifuged at 500×G for 5 minutes at 4° C. and the supernatant can be collected and stored at −80° C. until further analysis to determine the expression levels of cytokines and chemokines. Cytokine and chemokine analysis can be performed by Eve Technology (Calgary, Alberta, Canada). The following biomarkers can be tested: These include Eotaxin, G-CSF, GM-CSF, IFNγ, IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-9, IL-10, IL-12(p40), IL-12(p70), IL-13, IL-15, IL-17A, IP-10, KC, LIF, LIX, MCP-1, M-CSF, MIG, MIP-1α, MIP-1β, MIP-2, RANTES, TNFα, and VEGF. All samples can be run in triplicate.
[0214] Key outcome measures Hemodynamic measurements including, for example, HR, LVPDP, CF, LVEDP, +dP / dT, CO, PVR, LAP, and pulmonary function measurements including, for example, oxygen-PaO2, PpvO2, OI, SO2, AaDO2, compliance, elastance, resistance, Cdyn, PEEP, Ccs, PIP, Rrs, Crs, Ers, and G (tissue dumping of the left lung) and pulmonary pressure, volume loops can be performed at baseline, at the beginning of the reperfusion phase, immediately before the treatment of autologous mitochondria or respiratory buffer, and at 1, 2, 3 hours of reperfusion. At the end of the reperfusion phase, bronchoalveolar lavage of the left and right lungs is performed. Biochemical and proteomic, cytokine, chemokine, and immune responses can be determined. Pulmonary inflammatory responses can be examined by analyzing PPI, OI, histology, and expression of inflammatory cytokines. Pulmonary apoptosis can be determined by TUNEL and pulmonary edema. Pre- and post-ischemic pulmonary function can be determined for each mitochondrial concentration, and biochemical and histological analyses can be performed to determine the efficacy of each concentration.
[0215] Statistical plan and data analysis Power analysis showed that a sample size of six animals per group provided greater than 85% power to detect a difference equal to two times the within-group standard deviation (α=0.05, two-tailed) and 82% to detect a difference equal to 2.5 times the within-group standard deviation (α=0.0083, two-tailed, Bonferroni adjusted significance levels for post-hoc comparisons between the five groups). For the presence or absence of a finding, six animals per group would have 95% power to detect an effect occurring in at least 40% of the animals, whereas 10 animals per group would have 95% power to detect an effect occurring in at least 26% of the animals. A sample of 10 animals can provide 80% statistical power (2-tailed α = 0.05, β = 0.20) to detect a mean difference of 10% or more between treatment and control groups, assuming a pooled standard deviation of 10% (significant number = 1.0), using an independent groups Student's t-test (nQuery Advisor version 7.0, Statistical Solutions, Cork, Ireland). This sample size can also provide 80% power to capture 24-h differences between groups, using the power of the Mann-Whitney U test. Based on preliminary testing and animal mortality, typically each experimental group consists of roughly 6-10 animals. Means ± standard errors of the mean for all data are calculated for all variables. Simple pre- and post-intervention comparisons are made using paired 2-tailed Student's T-tests if the data are normally distributed, or Wilcoxon signed-rank tests for other continuous data. When there is only a single normally distributed variable for an animal, one-way analysis of variance is used to compare groups and an extension of the generalized linear model framework is used to assess the effects of other variables. When there are multiple measurements for an animal, a mixed model analysis of variance (MM-ANOVA) can be used to assess statistical significance with group and / or drug as fixed effects and incorporating repeated measures over time as within-group subject factors. In general, autoregressive (AR(1)) correlation can be used to model the association between measurements over time. AR(1) is a standard method for modeling data over time, meaning that measurements close to each other are more correlated than measurements further apart.For variables that are not normally distributed, data transformations can be performed to normalize the data (eg, log transformation) or the data can be analyzed using generalized estimating equations.
[0216] statistical significance A threshold of P<0.05 indicates statistical significance. Post-hoc comparisons between groups are adjusted for multiple comparisons using the Bonferroni correction. Efficacy can be compared using Fisher's exact test. Randomization can be performed using the R software package, based on 1:1 allocation using a uniform (0, 1) number generator. Statistical analysis can be performed using SAS version 9.3 (SAS Institute, Cary, NC).
[0217] result Exogenous mitochondria prepared in an aerosol form and administered to the airways are expected to be sufficient to ameliorate symptoms in a porcine ALI model.
[0218] Example 7: Exogenous mitochondria prepared in an aerosol form and administered to the airways are sufficient to ameliorate symptoms in a mouse ALI model To evaluate whether exogenous mitochondria prepared in an aerosol form and administered to the airways of mice are sufficient to ameliorate symptoms of acute pulmonary ischemia (ALI) in a mouse ALI model, aerosols containing labeled mitochondria were prepared and administered using a nebulizer system, and assays were performed to evaluate lung function and integrity.
[0219] method animal Male C57BL / 6J mice (8–10 weeks old, n = 35, Jackson Laboratory, Bar Harbor, ME) were used. All experiments were approved by the Boston Children's Hospital Institutional Animal Care and Use Committee and conformed to the National Institutes of Health Guide for the Care and Use of Animals.
[0220] Isolation of mitochondria Gastrocnemius muscles from C57BL / 6J mice (n=6) were excised and immediately used to isolate syngeneic mitochondria. Mitochondria were isolated and the number and viability of isolated mitochondria were determined as described above. Isolated mitochondria were suspended in either 0.3 mL of respiratory buffer (250 mmol / L sucrose, 20 mmol / L K+-HEPES buffer, pH 7.2, 0.5 mmol / L K+-EGTA, pH 8.0) for the vascular delivery group or 90 μL of respiratory buffer for the aerosol delivery group and immediately used for mitochondrial transplantation.
[0221] Murine pulmonary IRI model The experimental protocol is shown in Figure 1. Surgery was performed by the procedure described above with some modifications. Briefly, C57BL / 6J mice (n=29) were anesthetized by intraperitoneal injection of sodium pentobarbital (100 mg / kg) and maintained with 0.5% isoflurane inhalation during surgery. Oral endotracheal intubation using a 20-gauge plastic catheter was performed, and mice were mechanically ventilated at a tidal volume of 10 mL / kg and a respiratory rate of 130-140 breaths / min. A left thoracotomy was performed at the third intercostal space to expose the left hilum. The left hilum was occluded at the end of expiration for 2 h using a microvascular clamp (Roboz Surgical Instrument Co., Gaithersburg, MD, USA), reducing the tidal volume to 7.5 mL / kg. The surgical incision was covered with gauze soaked in a heparin solution containing (60 UI / 1 ml of heparin). At the end of the ischemic period, the clips were removed. Animals were randomly divided into two experimental groups: vascular delivery (V) group or nebulization (Neb) group. In the vascular delivery group, 1 × 10 8 Either 3 × 10 mitochondria (Mito V, n = 6) or 0.3 mL of respiratory buffer (Vehicle V, n = 7) were delivered to the left lung via injection into the left pulmonary artery using a tuberculin syringe with a 40-gauge needle. For delivery via nebulization at the onset of reperfusion, 3 × 10 mitochondria in 90 μL of respiratory buffer were delivered. 8Either 10 mitochondria (Mito Neb, n=6) or 90 μL of respiratory buffer (Vehicle Neb, n=6) was delivered to the whole lung for a total time of 40 seconds (10 seconds of nebulization followed by 1 minute of periodic mechanical ventilation, repeated 4 times). Mice were allowed to recover and returned to their cages for 24 hours. Sham control mice (Sham, n=4) were opened without hilar clamps and mechanically ventilated for 2 hours before being returned to their cages.
[0222] Mitochondrial biodistribution and uptake In additional experiments, Wistar rats (200-250 g, n = 6, Charles River Laboratories, Worcester, MA) were used for visualization of mitochondrial uptake in the lung. Donor rats (n = 2) were used for syngeneic mitochondrial isolation and 18 F-rhodamine 6G was used for mitochondrial labeling. Wistar rats (n = 3) were anesthetized and maintained with 2-3% isoflurane inhalation. Then, in one set of rats, a sternotomy was performed to expose the pulmonary trunk. 18 F-rhodamine 6G-labeled mitochondria (1 × 10 in 0.5 mL of respiration buffer) 9 ) were delivered to the lungs via injection into the pulmonary trunk using a tuberculin syringe with a 30-gauge needle.
[0223] In another group of Wistar rats (n=3), 18 F-rhodamine 6G-labeled mitochondria (1 × 10 in 0.3 mL of respiration buffer) 9 ) were delivered as an aerosol to the lungs via nebulization. Ten minutes after mitochondrial delivery, animals were euthanized in a CO2 chamber and imaged by positron emission tomography (PET) and microcomputed tomography (μCT).
[0224] In another set of C57BL / 6J mice (n = 4), as previously described 29Mitochondria were isolated from human cardiac fibroblasts and delivered to mouse lung tissue via a nebulizer and through the pulmonary artery. The use of human mitochondria in mouse lungs allowed for the differentiation of endogenous mouse mitochondria from transplanted human mitochondria based on immunoreactivity to a monoclonal anti-human mitochondrial antibody (biotin-MTCC2, Abcam, Cambridge, MA). Mitochondria were detected using an anti-human mitochondrial antibody and visualized with Vectastain (Vector Laboratories, Burlingame, CA) and AEC+ substrate chromogen (Dako, Agilent, Santa Clara, CA) as described above.
[0225] Pulmonary function After 24 h of reperfusion, mice were anesthetized by intraperitoneal injection of sodium pentobarbital (70 mg / kg). Tracheotomy and endotracheal intubation were performed with a plastic 18-gauge catheter, and mice were mechanically ventilated. A median laparotomy and sternotomy were then performed to expose the lungs, and the right hilum was clamped to assess the function of the injured left lung. TV was reduced to 5 mL / kg, and mice were then connected to a specialized rodent ventilator (FlexiVent, SCREQ, Montreuil, Quebec, Canada) to assess dynamic compliance of the respiratory system, resistance of the respiratory system, tissue damping (as an index of peripheral tissue resistance), maximum inspiratory pressure, and respiratory capacity of the left lung.
[0226] tissue analysis After 24 hours of reperfusion, the left lungs were harvested and each lung was divided into three portions.
[0227] The upper part of the left lung was used to assess tissue edema by calculating the wet / dry (w / d) weight ratio. Lungs were weighed immediately after collection (wet weight) and then weighed again (dry weight) after 72 h in a 70°C oven, and the w / d weight ratio was calculated.
[0228] The central part of the left lung was immediately fixed in 10% formalin. The tissue was embedded in paraffin and sectioned at 5 μm thickness. Serial sections were used for hematoxylin and eosin (H&E) staining, myeloperoxidase staining, and TUNEL assay.
[0229] H&E stained sections were assessed for severity of lung injury using the scoring system described above. Five random (15x) fields per section were analyzed. Lung injury was graded using the following: grade 1 represented normal lung histology, grade 2 showed mild neutrophilic leukocyte infiltration and mild to moderate interstitial congestion, grade 3 represented moderate neutrophilic leukocyte infiltration, perivascular edema formation and partial destruction of lung architecture, and grade 4 included dense neutrophilic leukocyte infiltration, abscess formation and complete destruction of lung architecture.
[0230] Myeloperoxidase (MPO) staining was performed as described above and sections were evaluated for neutrophil infiltration. Neutrophil counts were determined in five random (15x) fields per section.
[0231] The TUNEL assay was performed as previously described 29 The number of TUNEL-positive nuclei was expressed as a percentage of total cells counted in 16 random (10x) fields per section.
[0232] The left lung base was analyzed for structural damage within the lung using transmission electron microscopy (TEM) as previously described.
[0233] Bronchoalveolar lavage (BAL) analysis After pulmonary function assessment, the left lung was BALed using 1 mL of saline. The BAL fluid was immediately centrifuged at 500×G for 5 min at 4°C, and the supernatant was collected and stored at −80°C until further analysis for determination of cytokine and chemokine expression levels by Eve Technology (Calgary, Alberta, Canada). The following biomarkers were tested: eotaxin, G-CSF, GM-CSF, IFNγ, IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-9, IL-10, IL-12(p40), IL-12(p70), IL-13, IL-15, IL-17A, IP-10, KC, LIF, LIX, MCP-1, M-CSF, MIG, MIP-1α, MIP-1β, MIP-2, RANTES, TNFα, and VEGF. All samples were run in triplicate.
[0234] statistical analysis All data were collected by an observer blinded to treatment. All data are expressed as the mean ± standard error of the mean (SEM). Statistical analysis was performed by the nonparametric Mann-Whitney U test for all data except BAL analysis results, where between-group comparisons were assessed by one-way ANOVA. Statistical significance was defined by exact two-tailed P < 0.05.
[0235] result Pulmonary uptake of radiolabeled mitochondria Delivered either via vascular delivery (Figure 9A) or spray (Figure 9B) 18 F-rhodamine 6G radiolabeled mitochondria were diffusely taken up by the lungs and were absent in other regions of the body.
[0236] Pulmonary tissue uptake of human mitochondria Exogenous mitochondria from human cardiac fibroblasts delivered either via vascular delivery (FIG. 10A) or nebulization (FIG. 10B) were detected in and around pulmonary endothelial cells, pneumocytes, parenchyma, and alveoli.
[0237] Lung function performance After 2 hours of ischemia and 24 hours of reperfusion, mice receiving mitochondria via vascular delivery had significantly increased dynamic compliance (10.79 ± 1.11 μL / cmH2O) and peak inspiratory volume (0.24 ± 0.02 mL), as well as significantly decreased resistance (2.02 ± 0.28 cmH2O), tissue damping (10.49 ± 0.91 cmH2O / mL) and peak inspiratory pressure (9.48 ± 0.40 cmH2O) compared to vehicle V (5.91 ± 0.46, 0.127 ± 0.01, 3.33 ± 0.40, 20.02 ± 2.75, and 11.96 ± 0.74, respectively, P < 0.05 for each, Figure 11A-E). All pulmonary function parameters in the Mito V group were not significantly different compared to sham lungs (9.75 ± 0.35, 0.18 ± 0.01, 1.51 ± 0.20, 9.46 ± 0.63, and 8.62 ± 0.20, respectively, P > 0.05, Figures 11A-E). All parameters in the vehicle V lungs were significantly different compared to sham lungs (P < 0.05), except for peak inspiratory volume (P > 0.05).
[0238] After 2 hours of ischemia and 24 hours of reperfusion, mice receiving mitochondria via nebulization had significantly increased dynamic compliance (7.88±1.05 μL / cmH2O) and peak inspiratory volume (0.18±0.02 mL), as well as significantly decreased resistance (2.13±0.23 cmH2O), tissue damping (13.63±1.55 cmH2O / mL), and peak inspiratory pressure (10.18±0.40 cmH2O) compared to vehicle Neb (5.13±0.93, 0.10±0.02, 4.74±0.83, 34.02±5.04, and 11.82±0.53, respectively, P<0.05 for each, Figure 12A-D).
[0239] All pulmonary function parameters in the Mito-Neb group were not significantly different compared to sham lungs (9.75 ± 0.35, 0.18 ± 0.01, 1.51 ± 0.20, and 9.46 ± 0.63, respectively, P > 0.05, Fig. 3D-F, I, J), except for peak inspiratory pressure (8.62 ± 0.20, P < 0.05). All parameters in the vehicle-Neb lungs were significantly different compared to sham lungs (P < 0.05).
[0240] Representative pressure-volume loops demonstrated that Vehicle V and Vehicle Neb had smaller lung volume capacity and higher pressure compared to Mito V, Mito Neb and Sham groups (Figure 13).
[0241] Lung tissue damage H&E analysis showed a significant reduction in inflammatory cell infiltration and interstitial congestion without signs of destruction of lung architecture in Mito V and Mito Neb lungs compared to Vehicle V and Vehicle Neb, respectively (grade 1.8±0.1, grade 2.5±0.1 for vascular delivery group, respectively; grade 1.7±0.1, grade 2.5±0.1 for nebulized group, respectively, both P<0.05, Figure 14, Figure 15A-E). Significantly improved preservation of lung tissue was observed in sham lungs compared to all groups (grade 1.3±0.1, P<0.05).
[0242] A significant reduction in neutrophil counts was observed in the Mito V and Mito Neb groups compared to Vehicle V and Vehicle Neb, respectively (120.2±5.5, 159.9±6.5 for vascular delivery, respectively, and 77.8±3.8, 125.7±4.9 for nebulization, respectively, all P<0.05, Figures 14, 15B, 15E). Neutrophil counts were significantly reduced in sham lungs compared to Mito V, Vehicle V, and Vehicle Neb lungs (55.3±3.6, P<0.05). No significant difference in neutrophil counts was observed in the sham group compared to Mito Neb (P>0.05).
[0243] TUNEL analysis showed a significant reduction in the number of apoptotic positive nuclei in the Mito V and Mito Neb groups compared with Vehicle V and Vehicle Neb, respectively (1.38±0.25, 1.55±0.18 for vascular delivery group, respectively; 3.1±0.38, 3.15±0.25 for nebulization group, respectively, both P<0.05). There was no significant difference in the number of apoptotic positive nuclei in the sham lung compared with the Mito V and Mito Neb groups (0.3±0.1, P<0.05) (Figure 14, Figure 15C, Figure 15F).
[0244] After 24 hours of reperfusion, TEM from the left lower lobe showed preserved endothelium and basement membrane in Vehicle V and Vehicle Neb and Mito V and Mito Neb, with no difference in the alveolar space, indicating no damage to the basement membrane (Figure 4).
[0245] There were no significant differences in percentage wet to dry weights between Vehicle V left (88.9 ± 0.5%) and right (87.1 ± 1.1%) lungs, Mito V left (88.5 ± 0.3%) and right (88.3 ± 0.6%) lungs, Vehicle Neb left (87.5 ± 1.1%) and right (89.2 ± 1.1%) lungs, Mito Neb left (88.5 ± 1.2%) and right (89.3 ± 0.6%) lungs, and Sham left (88.7 ± 1.0%) and right (90.1 ± 1.0%) lungs, P > 0.05 for each, FIG. 15G.
[0246] Bronchoalveolar lavage cytokines At 24 hours of reperfusion, there were no significant differences in cytokines and chemokines between groups (Figure 16).
[0247] Consideration Mitochondrial damage, consisting of reactive oxygen species-induced toxicity, cellular bioenergetics failure, upregulation of apoptosis, cytokine production, and innate immunity during IRI, plays a significant role in acute lung injury. In this study, we demonstrated the efficacy and safety of mitochondrial transplantation in a mouse model of pulmonary IRI. After 24 hours of reperfusion following ischemic injury, mitochondrial transplantation improves pulmonary functional performance and reduces lung tissue injury.
[0248] Previous studies investigating mouse pulmonary IRI utilized ischemia times of 60 to 90 minutes. These experiments provided detailed analysis of lung tissue injury. However, the experiments either did not provide any functional analysis or measured lung function in a non-physiological isolated ex vivo system. In our study, we used the FlexiVent machine to achieve in vivo functional measurements. Based on our preliminary experiments, we selected an ischemia time of 2 hours. A shorter ischemia time would have resulted in insufficient pulmonary IRI and would not have allowed for functional assessment and comparative analysis between our study groups. 18 F-Rhodamine 6G radiolabeled mitochondria were used to demonstrate the distribution of delivered mitochondria. We delivered radiolabeled mitochondria via either vascular delivery or nebulization. Our results show mitochondrial distribution throughout the lung in both groups. Mitochondria delivered via nebulization as an aerosol were found along the trachea and bronchial tree, suggesting that mitochondria are already attached to airway tissue during initial contact.
[0249] In our study, human mitochondria were used to determine the cellular uptake of transplanted mitochondria. Human mitochondria allow targeted labeling of transplanted mitochondria, thus eliminating the possibility of labeling endogenous mouse mitochondria. Human mitochondria were found in all cells throughout the lung, demonstrating that mitochondria delivered either via the vasculature or aerosol were effectively transplanted.
[0250] Two different mitochondrial delivery methods were used in this study. The mitochondria can be delivered via the vascular system to the targeted organ. Delivery via nebulization was used as an additional test group to allow for a less invasive, yet still clinically relevant and easily utilized method. After 24 hours of reperfusion, significant functional improvements were observed in lungs administered mitochondria via both vascular delivery and nebulization compared to vehicle lungs. In one functional parameter, PIP, a significant difference was observed between Mito V and Vehicle V, but no significant difference was observed when comparing Mito Neb and Vehicle Neb. This could imply an increased efficacy of mitochondria delivered via the vascular system. However, this observation could be explained by the fact that mitochondria delivered via nebulization are not delivered as far as mitochondria delivered via the vascular system, and delivering a higher concentration of mitochondria would be preferable for reasons of uptake into the trachea and bronchial tree as well. Experiments can be performed to determine the optimal mitochondrial concentration delivered by nebulization is required. It is also important to note that histological analysis showed a significant improvement in cell viability after 24 hours of reperfusion in both Mito V and Mito Neb compared to the Mito V and Mito Neb vehicle groups.
[0251] In conclusion, we have demonstrated the efficacy and safety of mitochondrial transplantation in a mouse model of pulmonary IRI. After 24 hours of reperfusion following ischemic injury, mitochondrial transplantation improves lung function and reduces lung tissue injury. These results suggest that this therapy can be used to protect lung tissue from IRI, thus reducing morbidity and mortality in several clinical scenarios, such as lung transplantation, cardiopulmonary resuscitation, pulmonary embolism, sepsis, and hypotensive events and procedures during cardiopulmonary bypass or mechanical circulatory support.
[0252] Other embodiments While the invention has been described in conjunction with the detailed description thereof, it is to be understood that the above description is intended to illustrate, but not to limit, the scope of the invention as defined by the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims. The present invention includes the following preferred embodiments. (1) A method for treating a subject suffering from a respiratory disorder, comprising administering to the subject via the airway a therapeutically effective amount of a composition comprising mitochondria. (2) The method according to (1), wherein the composition is an aerosolized composition. (3) The method according to (1), wherein the composition is converted into an aerosol form prior to administration to a subject by using a nebulizer, a vaporizer, a nasal spray, a pressurized metered dose inhaler, or a breath-activated pressurized metered dose inhaler. (4) The method according to (3), wherein the aerosol form of the composition comprises droplets having a median size of 1 to 1000 microliters. (5) The method according to (1), wherein the composition comprises mitochondria capable of responding to respiration. (6) The method according to (1), wherein the subject is suffering from respiratory failure, respiratory depression, pneumonia, lung cancer, wrinkles, alopecia, and / or cancer. (7) The method according to claim 1, wherein the subject is suffering from acute lung injury. (8) The concentration of mitochondria in the composition is about 1 × 10 5 ~5×10 8 ml -1 The method according to (1), (9) Subjects were administered approximately 1 × 10 5 ~1×10 9 The method according to (1), wherein a single mitochondria is administered. (10) The method according to (1), wherein the mitochondria are autologous, allogeneic, or xenogeneic. (11) The composition has a pH of 7 to 8. + The method according to (1), further comprising a solution selected from the group consisting of HEPES, saline, phosphate buffered saline (PBS), serum, and plasma. (12) The method according to (1), wherein the composition further comprises one or more osmolytes selected from the group consisting of trehalose, sucrose, mannose, glycine, proline, glycerol, mannitol, sorbitol, betaine, and sarcosine. (13) The method according to (1), wherein the composition further comprises a pharmaceutical agent. (14) The method according to (1), wherein the composition further comprises a pharma- ceutical acceptable diluent, excipient, or carrier. (15) The method of (1), wherein the composition further comprises a therapeutic or diagnostic agent, and the therapeutic or diagnostic agent is covalently linked to, embedded within, or internalized within the mitochondria. (16) The method according to (15), wherein the therapeutic or diagnostic agent is a therapeutic diagnostic agent. (17) The method according to (15), wherein the therapeutic or diagnostic agent comprises an antibody or an antigen-binding fragment thereof. (18) The method according to (15), wherein the therapeutic or diagnostic agent is covalently linked to the mitochondria. (19) The method according to (15), wherein the therapeutic or diagnostic agent is embedded in or internalized within mitochondria. (20) The method according to (1), wherein the mitochondria are genetically modified. (21) The method according to (1), wherein the mitochondria contain an exogenous polypeptide. (22) The method according to (1), wherein the mitochondria contain an exogenous polynucleotide, DNA, RNA, mRNA, microRNA, nuclear RNA, or siRNA. (23) The method according to (1), wherein the mitochondria are viable mitochondria capable of respiratory response. (24) An aerosolized composition comprising: A plurality of droplets comprising a buffer solution, at least one droplet in the plurality of droplets comprising: The plurality of droplets comprising at least one mitochondrion. The aerosolized composition comprising: (25) The aerosolized composition according to (24), wherein the buffer is selected from the group consisting of K+-HEPES having a pH of 7 to 8, saline, phosphate buffered saline (PBS), serum, and plasma. (26) The aerosolized composition of (24), further comprising one or more osmolytes selected from the group consisting of trehalose, sucrose, mannose, glycine, proline, glycerol, mannitol, sorbitol, betaine, and sarcosine. (27) The aerosolized composition according to (24), further comprising a pharmaceutical agent. (28) The aerosolized composition according to (24), further comprising a pharma- ceutically acceptable diluent, excipient, or carrier. (29) The aerosolized composition of (24), wherein the composition further comprises a therapeutic or diagnostic agent, and the therapeutic or diagnostic agent is covalently linked to, embedded within, or internalized within the mitochondria. (30) The aerosolized composition of (29), wherein the mitochondrial drug is selected from the group consisting of a therapeutic drug, a chemotherapeutic drug, or a diagnostic drug. (31) The aerosolized composition described in (29), wherein the mitochondrial drug comprises an antibody or an antigen-binding fragment. (32) The aerosolized composition described in (29), wherein the mitochondrial drug is covalently linked to the mitochondria. (33) The aerosolized composition described in (29), wherein the mitochondrial drug is embedded in or internalized within mitochondria. (34) The aerosolized composition of (24), wherein the droplets have a median size of 1 to 1000 microliters. (35) The aerosolized composition described in (24), wherein the mitochondria are genetically modified. (36) The aerosolized composition described in (24), wherein the mitochondria contain an exogenous polypeptide. (37) The aerosolized composition described in (24), wherein the mitochondria contain an exogenous polynucleotide. (38) The aerosolized composition described in (24), wherein mitochondria are incubated with a composition containing an enzyme prior to administration to a subject. (39) The aerosolized composition according to (24), comprising autologous mitochondria, homologous mitochondria, heterologous mitochondria, or a mixture thereof. (40) Approximately 1×10 3 ~Approx. 1×10 14 pieces, about 1×10 4 ~Approx. 1×10 13 pieces, about 1×10 5 ~Approx. 1×10 12 pieces, about 1×10 6 ~Approx. 1×10 11 pieces, about 1×10 7 ~Approx. 1×10 10 pieces, about 1×10 3 ~Approx. 1×10 7 pieces, about 1×10 4 ~Approx. 1×10 6 pieces, about 1×10 7 ~Approx. 1×10 14 pcs, or about 1 x 10 8 ~Approx. 1×10 13 pieces, about 1×10 9 ~Approx. 1×10 12 pieces, about 1×10 5 ~Approx. 1×10 8 1 x 10 or at least or about 1 x 10 3 pieces, 1×10 4 pieces, 1×10 5 pieces, 1×10 6 pieces, 1×10 7 pieces, 1×10 8 pieces, 1×10 9 pieces, 1×10 10 pieces, 1×10 11 pieces, 1×10 12 pieces, 1×10 13 1 x 10 or at least or about 1 x 10 14 The aerosolized composition according to (24), comprising mitochondria. (41) A device for delivering mitochondria to a subject via the airway, comprising: A housing and a reservoir disposed within the housing for a composition comprising mitochondria; an aerosol generator for generating the composition in aerosolized form; an outlet through which the composition is delivered to the airway of a subject; The above device. (42) The device according to (41), wherein the device is a nebulizer, a nasal spray, or a sprayer. (43) The apparatus according to (41), wherein the aerosol generator is an ultrasonic nebulizer. (44) The device according to (41), wherein the aerosol generator is a vibrating mesh device. (45) The apparatus of (41), wherein the aerosol generator comprises an air compressor that blows compressed air through the composition to convert the composition into an aerosol form. (46) A device for delivering mitochondria to a subject via the airway, comprising: A housing and A composition comprising mitochondria disposed within a housing; an outlet configured to deliver the composition from the housing to the respiratory tract of the subject and aerosolize the composition as it passes therethrough; The above device. [Sequence List Free Text]
[0253] Sequence Listing 1 <223> Primers for mouse mMitoF1 Sequence Listing 2 <223> Primers for mouse mMitoR1 Sequence Listing 3 <223> Primers for mB2MR1 Sequence Listing 4 <223> Primers for mB2MR1
Claims
1. An aerosolized composition for treating a subject suffering from a respiratory disorder, comprising a therapeutically effective amount of an isolated mitochondrial or complex mitochondrial drug, The complex mitochondrial drug comprises isolated mitochondria and an agonist, the agent is linked to, bound to, embedded in, or encapsulated by mitochondria; and The aerosolized composition is administered to a subject via the respiratory tract. The aerosolized composition described above.
2. The aerosolized composition of claim 1, wherein the aerosolized composition is converted into aerosol form prior to administration to a subject by using a nebulizer, a vaporizer, a nasal spray, a pressurized metered dose inhaler, or a breath-activated pressurized metered dose inhaler.
3. The aerosolized composition of claim 2, wherein the aerosol form of the aerosolized composition comprises droplets having a median size of 1 to 1000 microliters.
4. The aerosolized composition of claim 1, wherein the aerosolized composition comprises isolated mitochondria capable of respiratory response.
5. 10. The aerosolized composition of claim 1, wherein the subject is suffering from respiratory failure, respiratory depression, pneumonia, lung cancer, wrinkles, alopecia, and / or cancer.
6. The aerosolized composition of claim 1 , wherein the subject is suffering from acute lung injury.
7. The concentration of isolated mitochondria in the aerosolized composition is about 1 x 10 5 ~5×10 8 ml -1 2. The aerosolized composition of claim 1, wherein
8. Subjects were administered approximately 1 x 10 5 ~1×10 9 2. The aerosolized composition of claim 1, wherein a single isolated mitochondria is administered.
9. The aerosolized composition has a pH of 7 to 8. + 10. The aerosolized composition of claim 1, further comprising a solution selected from the group consisting of HEPES, saline, phosphate buffered saline (PBS), serum, and plasma.
10. An aerosolized composition for treating a subject suffering from a respiratory disorder, comprising a plurality of droplets comprising a buffer, At least one droplet in the plurality of droplets is at least one isolated mitochondrial or complex mitochondrial drug, The complex mitochondrial drug comprises at least one isolated mitochondrion and an agonist, the agent is linked to, bound to, embedded in, or encapsulated by mitochondria; The aerosolized composition described above.
11. 11. The aerosolized composition of claim 10, wherein the buffer is selected from the group consisting of K+-HEPES having a pH of 7-8, saline, phosphate buffered saline (PBS), serum, and plasma.
12. 11. The aerosolized composition of claim 1 or claim 10, further comprising one or more osmolytes selected from the group consisting of trehalose, sucrose, mannose, glycine, proline, glycerol, mannitol, sorbitol, betaine, and sarcosine.
13. 11. The aerosolized composition of claim 1 or claim 10, further comprising a pharmaceutical agent.
14. 11. The aerosolized composition of claim 1 or claim 10, further comprising a pharma- ceutically acceptable diluent, excipient, or carrier.
15. The aerosolized composition of claim 1 or claim 10, wherein the active agent is a therapeutic or diagnostic agent, and the therapeutic or diagnostic agent is covalently linked to, embedded within, or internalized within the mitochondria.
16. The aerosolized composition of claim 15, wherein the active agent is covalently linked to the mitochondria.
17. The aerosolized composition of claim 15, wherein the active agent is embedded within the mitochondria or internalized within the mitochondria.
18. The therapeutic or diagnostic agent is a therapeutic diagnostic agent; the therapeutic or diagnostic agent comprises an antibody or an antigen-binding fragment thereof; The therapeutic or diagnostic agent is covalently linked to the mitochondria; or 16. The aerosolized composition of claim 15, wherein the therapeutic or diagnostic agent is embedded or internalized within mitochondria.
19. The agent is selected from the group consisting of a therapeutic agent, a chemotherapeutic agent, and a diagnostic agent; or the agent comprises an antibody or an antigen-binding fragment; 18. The aerosolized composition of claim 16 or 17.
20. 11. The aerosolized composition of claim 10, wherein the plurality of droplets has a median size of 1 to 1000 microliters.
21. An aerosolized composition described in claim 1 or claim 10, wherein the isolated mitochondria are genetically modified.
22. An aerosolized composition described in claim 1 or claim 10, wherein the isolated mitochondria contain an exogenous polypeptide.
23. The aerosolized composition of claim 1 or claim 10, wherein the isolated mitochondria contain an exogenous polynucleotide, DNA, RNA, mRNA, microRNA, nuclear RNA, or siRNA.
24. The aerosolized composition of claim 1 or claim 10, wherein the isolated mitochondria are viable, respiratory competent mitochondria.
25. 11. The aerosolized composition of claim 1 or claim 10, wherein the isolated mitochondria prior to administration to a subject are incubated with a composition comprising an enzyme.
26. The aerosolized composition of claim 1 or claim 10, wherein the isolated mitochondria are selected from autologous mitochondria, homologous mitochondria, heterologous mitochondria, or a mixture thereof.
27. Approximately 1×10 3 ~Approx. 1×10 14 pieces, approximately 1 x 10 4 ~Approx. 1×10 13 pieces, approximately 1 x 10 5 ~Approx. 1×10 12 pieces, approximately 1 x 10 6 ~Approx. 1×10 11 pieces, approximately 1 x 10 7 ~Approx. 1×10 10 pieces, approximately 1 x 10 3 ~Approx. 1×10 7 pieces, approximately 1 x 10 4 ~Approx. 1×10 6 pieces, approximately 1 x 10 7 ~Approx. 1×10 14 pcs, or about 1 x 10 8 ~Approx. 1×10 13 pieces, approximately 1 x 10 9 ~Approx. 1×10 12 pieces, approximately 1 x 10 5 ~Approx. 1×10 8 1 x 10 or at least or about 1 x 10 3 pieces, 1×10 4 pieces, 1×10 5 pieces, 1×10 6 pieces, 1×10 7 pieces, 1×10 8 pieces, 1×10 9 pieces, 1×10 10 pieces, 1×10 11 pieces, 1×10 12 pieces, 1×10 13 1 x 10 or at least or about 1 x 10 14 11. The aerosolized composition of claim 1 or claim 10, comprising isolated mitochondria.
28. The aerosolized composition of claim 1, comprising a therapeutically effective amount of isolated mitochondria.
29. The aerosolized composition of claim 1, comprising a therapeutically effective amount of a complex mitochondrial drug.
30. The aerosolized composition of claim 10, comprising a therapeutically effective amount of isolated mitochondria.
31. The aerosolized composition of claim 10, comprising a therapeutically effective amount of a complex mitochondrial drug.
Citation Information
Patent Citations
Therapeutic Uses of Mitochondria and Combined Mitochondrial Agents
JP2019507729A
